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Abstract 
Lithium is regarded as the first-line pharmacotherapy for the treatment of acute mood 
episodes, suicide prevention and prophylactic treatment in patients with bipolar disorder 
(BPD).  Response to lithium has a strong genetic component and lithium-responders have an 
increased frequency of BPD among their family members. Lithium has a narrow therapeutic 
index and 75-90% of patients on long-term lithium treatment experience one or more side 
effects, such as weight gain, cognitive decline and skin problems, amongst at least 20 side 
effects.  
The research project is immersed in a larger project on the genetics of bipolar disorder, in 
which a large number of individuals in families have been investigated over several years.  
The present pilot study explored whether single nucleotide polymorphisms (SNPs) within 
GSK3B, AKT1, ARRB2, GRIA2 and PPPARGC1A could be associated with the incidence and 
severity of lithium-induced side effects. One hundred and five patients with a diagnosis of 
BPD type I and a history of treatment with lithium were genotyped for ten SNPs within the 
candidate genes using SNaPshot PCR, TaqMan SNP genotyping and RFLP analysis. A 
questionnaire related to the twenty most common side effects, as well as treatment history, 
was conducted with all patients.  
Results show an association between the cognitive side effects of lithium treatment, such as 
memory and concentration difficulties, and the splice-variant rs6438552 in GSK3B, an 
association between weight gain and rs1130233 in AKT1, as well as an association between 
skin side effects, related to lithium treatment, and the coding variant rs8192678, in 
PPARGC1A. Chi-squared analysis further indicated associations between polydipsia and body 
aches with variants in PPARGC1A, and associations of nausea with rs10138227 in AKT1 and 
indigestion with rs4302506 in GRIA2. These four associations did not remain significant 
when covariates were taken into account using logistic regression analysis. 
Although exploratory, these results indicate that at least some of the genes investigated in 
this study may play a role in influencing interindividual susceptibility to lithium-induced side 
effects, and may be clinically important in the treatment of BPD patients. This sets the stage 
for a larger scale study aimed at understanding appropriate treatment for this debilitating 
and often fatal disorder.  
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Chapter 1. Introduction 
1.1. Features and Characteristics of Bipolar Disorder  
Bipolar Disorder (BPD) is a chronic psychiatric illness.  The more severe form, Type 1, which 
has a world-wide prevalence of 0.6 – 1 % (Merikangas et al., 2007; Merikangas et al., 2011) is 
characterised by recurrent episodes of mania and depression. Psychotic features such as 
delusions and hallucinations may also be a feature (American Psychiatric Association, 1994). 
The affected individual usually experiences a decline in quality of life, productivity, and 
longevity, as well as having greater difficulty in sustaining interpersonal relationships and 
maintaining employment, compared to those without mood disorders (Calabrese et al., 
2003a).  
BPD is a major public health problem with severe socioeconomic implications. In 2009, the 
total economic burden of BPD in the USA was estimated at US $151 billion, the cost of which 
is attributed to treatment, hospitalisation, misdiagnosis, and consequent productivity loss 
(Hirschfeld and Vornik, 2005; Dilsaver, 2011). Nearly one third of patients admits to 
attempting suicide at least once and between 10% and 20% of patients successfully commit 
suicide (Müller-Oerlinghausen et al., 2002).  
The diagnosis of BPD is based exclusively on clinical symptoms as the molecular pathology 
has not been discovered (Phillips and Kupfer, 2013). Due to the symptomatic overlap 
between BPD and other psychiatric disorders, such as Unipolar Depression and 
Schizophrenia, an accurate clinical diagnosis is difficult to make (Maier et al., 2005). Patients 
are often misdiagnosed or diagnoses are delayed and their disease is not effectively treated 
and managed.  
The aetiology of BPD is still poorly understood, but the disease is known to involve genetic 
and epigenetic (Abdolmaleky et al., 2006; D'Addario et al., 2012) mechanisms as well as 
environmental factors (Alloy et al., 2005). Genetic variation amongst affected individuals has 
been investigated in order to determine the factors underlying the pathophysiology of BPD. 
The majority of genetic studies suggest that BPD has a high level of genetic heterogeneity 
and a substantial polygenic component (Craddock et al., 1995). Meta-analyses have found 
consistent supportive evidence for linkage to a few potential BPD susceptibility loci 
especially on chromosomes 6q, 8q, 13q and 22q (Badner and Gershon, 2002; Segurado et al., 
2003; McQueen et al., 2005).  
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Polymorphisms in a variety of candidate genes have been tested for association with BPD, 
but the small number that appear to be associated show odds ratios of 1.1–1.3, which is 
consistent with a polygenic basis for the disease (Nurnberger et al., 2008). Several genome-
wide association studies (GWAS) have been conducted, but few associations have been 
replicated in more than one study (Sklar et al., 2011). Apart from the locus heterogeneity 
model of BPD, it is hypothesised that it is the regulatory elements, and not necessarily the 
coding or structural component of genes associated with psychiatric disorders that may be 
disrupted (Perkins et al., 2004).  
As no biological markers for BPD currently exist, neuro-imaging studies have been conducted 
to examine structural changes in brain regions involved in mood and behaviour (Adler et al., 
2006; Scherk et al., 2008). Meta-analysis has shown that BPD patients have reduced 
cerebellar volumes compared to healthy controls (De Peri et al., 2012). 
1.2. Diagnosis of BPD 
The diagnosis of BPD is hindered by several factors, including the symptomatic overlap with 
other psychiatric disorders, as well as comorbidity with other illnesses. BPD patients often 
have another Axis I (or II) disorder which can complicate diagnosis and treatment (McElroy 
et al., 2001). These disorders include substance and alcohol abuse, anxiety and panic 
disorders, and personality disorder. 
According to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV), BPD type I is marked by the occurrence of one or more Manic Episodes or Mixed 
Episodes (American Psychiatric Association, 1994). One or more Major Depressive Episodes 
is also often present. Patients that experience a milder form of mania (hypomania), without 
psychotic symptoms and without harmful behaviour to themself, or others, are diagnosed as 
having BPD type II.   
1.2.1. Description of Mania 
A manic state is an immense disturbance of emotion that is characterised by euphoria, 
overactivity, flight of ideas, and positive psychomotor signs (American Psychiatric 
Association, 1994). When untreated, a manic phase can last months or years (Belmaker, 
2004). Manic episodes are accompanied by an increase in mental and physical energy, which 
may be seen in the form of pressured speech, sexual promiscuity, racing thoughts, 
distractibility, psychomotor agitation and a decreased need for sleep (American Psychiatric 
Association, 1994).  
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A manic state is not always stable and it may be interrupted by tearfulness, or intense 
irritability, hostility, or even aggressiveness (Akiskal, 1995). This is termed a mixed episode, 
as manic and depressive symptoms are observed simultaneously. The loss of self-control and 
inhibition experienced during mania often leads to damaged relationships and financial 
debt, which only serves to worsen the depressive episode following mania (Goodwin and 
Jamison, 2007). 
1.2.2. Description of Depression 
BPD patients with bipolar depression experience psychological feelings of worthlessness, 
inappropriate guilt, and have the inability to concentrate or think clearly. This is 
accompanied by a number of physical disturbances, including insomnia or hypersomnia, 
weight gain or loss, psychomotor agitation or retardation, fatigue and lassitude (American 
Psychiatric Association, 1994). Psychotic features may also present that often have themes 
of worthlessness, sinfulness and persecution (Akiskal, 1995). 
1.3. Bipolar Disorder in South Africa 
In spite of the high burden of BPD and other psychiatric conditions in the world, few 
epidemiological needs assessment surveys have been carried out in sub-Saharan Africa 
(Ovuga et al., 2005). Due to several factors, the South African population is at high risk for 
psychiatric disorders (Kessler et al., 2007). A major concern is the history of political violence 
and victimisation of the Apartheid era, as well as the increasingly high rates of violent crimes 
and violence against women and children in the post-Apartheid era (Dunkle et al., 2004; 
Dinan et al., 2004). In addition, it has been reported that the harsh economic circumstances 
and the risk of HIV/AIDS could contribute to higher rates of emotional distress (Seedat and 
Stein, 2000; Hughes et al., 2006). The available evidence suggests high and ever increasing 
suicide rates (Flisher et al., 2004) and high levels of alcohol abuse in South Africa (Parry et 
al., 2005). 
The South African Stress and Health Study (SASH) was conducted as part of the WHO World 
Mental Health (WMH) Survey Initiative from January 2002 to June 2004 (Kessler et al., 2007). 
The study found the prevalence of psychiatric disorders to be notably higher in SASH than in 
a number of other country-wide surveys. Markedly, the prevalence of substance abuse in 
South Africa, i.e. 5.8%, was at least twice that in other WMH countries, except for the 
Ukraine, where it is 6.3% (Williams et al., 2008).  
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BPD was not evaluated in isolation, but the 12-month prevalence of all mood disorders was 
estimated to be 5% (Herman et al., 2009). In the Western Cape province of South Africa, the 
prevalence of BPD is estimated to be 1%, and it is the most common reason for admission of 
female patients to Acute Psychiatric Services (Kleintjes et al., 2006).  
1.4. Treatment of Bipolar Disorder: Mood stabilisers, 
Anticonvulsants, Antipsychotics and Antidepressants 
The long-term treatment of BPD is through several classes of drugs, such as anticonvulsants, 
antipsychotics (especially the atypical antipsychotics) and lithium, collectively termed “mood 
stabilisers”. Although they differ in chemical structure and mechanism of action, all these 
drugs commonly act as prophylactic agents in the prevention of illness recurrence. A mood 
stabiliser should ideally be effective in the treatment of acute manic symptoms, acute 
depressive symptoms, as well as in the prevention of manic and depressive symptoms 
(Bauer and Mitchner, 2004). 
Lithium is regarded as the first-line treatment for prevention of further episodes in BPD1 
(APA, 2002; Lewis et al., 2010; Yatham et al., 2013). Among anticonvulsants, valproic acid 
(VPA), lamotrigine (LTG) and carbamazepine (CBZ) have been shown to be effective in the 
long-term management of BPD (Muzina et al., 2005; Bowden, 2009). VPA, CBZ, as well as 
lithium can be used in the treatment of acute mania, but it has been suggested that these 
drugs work too slowly in the majority of patients with acute mania (Verdoux et al., 1996). 
LTG on the other hand, is especially effective in the treatment of bipolar depression 
(Passmore et al., 2003). 
Antipsychotics are very effective in the treatment of acute mania (Biederman et al., 1979), 
although long-term use is avoided due to the risk of developing tardive dyskinesia. As these 
drugs can be administered parenterally and have a rapid effect, they are especially critical 
for acute treatment in violent or psychotic patients (Belmaker, 2004). The atypical 
antipsychotics, which cause less severe extrapyramidal side effects, are also effective in the 
treatment of mania and may additionally have a lower risk of inducing depression than the 
classic antipsychotics. Their utility in the long-term management of BPD is, however, 
controversial as patients may have increased risk for developing severe adverse drug 
reactions while on maintenance treatment (Vieta and Goikolea, 2005).  
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Bipolar depression is generally treated with tricyclic antidepressants, selective serotonin-
reuptake inhibitors, and monoamine oxidase inhibitors (Kusumakar, 2002), as in patients 
with unipolar depression. However, more care should be taken in bipolar patients as 
antidepressants may induce mania. Antidepressants are, therefore, avoided in patients with 
a history of dangerous manic episodes, in which the life of the patient, his family or his job 
were endangered (Belmaker, 2004).   
The “Standard Treatment Guidelines and Essential Drugs List for South Africa” provides 
standard treatment guidelines for the treatment of BPD in South Africa (The National 
Department of Health, 2012).  A summary of these drugs, the drug type and the aspects of 
treatment it is used for are given in Table 1.1. 
Table 1.1: Drugs included in the “Standard Treatment Guidelines and Essential Drugs List 
for South Africa” for the treatment of bipolar disorder 
Drug Treatment Drug type 
Lithium Maintenance, Depressive 
episodes 
Mood stabiliser 
Sodium Valproate Maintenance, Mixed 
Episodes 
Anticonvulsant 
Fluoxetine Depressive episodes Antidepressant 
Carbamazepine Mixed episode Anticonvulsant 
Haloperidol Acute managements, 
Psychosis 
Antipsychotic 
Benzodiazepines Acute management Anticonvulsant 
Chlorpromazine Psychosis Antipsychotic 
FTD; FZD; ZD Psychosis Antipsychotic 
Clozapine Psychosis Atypical antipsychotics 
Rispiridone Psychosis Atypical antipsychotics 
Sulpiride Psychosis Atypical antipsychotics 
FTD-Flupenthixol decanoate, FZD-Fluphenazine decanoate, ZD-Zuclopenthixol decanoate 
Combination treatment, or polypharmy, is the rule rather than the exception in BPD patients 
and most patients are on a combination of lithium or VPA, an antidepressant and/or an 
atypical antipsychotic (with a median total of three medications) (Post et al., 2010). In spite 
of the multiple therapeutic tools used in the treatment of BPD, a significant number of 
patients may still not respond to treatment, even after consecutive trials with various drugs. 
Drug combinations can cause neurotoxicity, which likely results from different drug 
interaction mechanisms (Boeker et al., 2011). A better understanding of mechanisms of drug 
action, and genetic factors involved in drug response, is therefore crucial to maximise 
treatment efficacy and to prevent dangerous side effects.  
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Pharmacogenetic or pharmacogenomic (PGx) studies aim to identify genetic variants that 
lead to interindividual differences in drug response and susceptibility to adverse drug 
reactions (ADRs). PGx studies can be divided into pharmacokinetic (PK) and 
pharmacodynamic (PD) approaches, where the former pertains to genetic variants that 
effect drug metabolism and the latter to genetic variants that have effects on drug targets, 
including downstream signalling pathways (Evans and Johnson, 2001). 
The prospect of pharmacogenetically determining effective personalised treatment is 
especially appealing in BPD, where patients are often treated with multiple drugs and where 
effective treatment is determined on a trial and error basis. Understanding the factors 
influencing response to treatment does not only hold the promise of better treatment for 
patients, but can also aid in elucidating the underlying genetic cause of BPD.   
The present study investigates lithium treatment in patients with BPD type I, with a focus on 
genetic factors that may influence the prevalence and severity of ADRs in these patients. 
Current knowledge on lithium’s mechanism of action and lithium-induced ADRs are 
discussed in Chapters 2 and 3, respectively. The materials and methods, results and 
discussion of the study are presented in Chapters 4 to 6. 
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Chapter 2. Lithium Treatment 
Lithium is a monovalent cation that was first used in the clinical treatment of BPD in the 
1950’s (Cade, 1949). Clinically, it remains the first line treatment, and is administered as a 
salt in carbonate or citrate formulations. Slow release and immediate release medications 
are available with the former producing relatively more stable plasma lithium levels. Due to 
the possibility of toxicity developing at high levels, lithium levels are carefully monitored and 
maintained at a therapeutic serum concentration of 0.6-1.2mEq/L.  
Numerous control and open trials have shown lithium to reduce episode recurrences by at 
least 30% (Carney and Goodwin, 2005; Coryell, 2009) and at optimal dosing, it reduces 50% 
of the recurrences (Calabrese et al., 2003b; Bowden et al., 2003). Lithium, further, has high 
efficacy in reducing the number of suicide attempts in patients with recurrent major 
affective disorders (Rihmer, 2011; Cipriani et al., 2013). 
Response to lithium has a strong genetic component and patients who respond to lithium 
generally have an increased frequency of BPD among their family members (Grof et al., 
1994; Grof et al., 2002; Cruceanu et al., 2008; Cruceanu et al., 2009). Lithium-responders 
tend to have euphoric mania, good inter-episode recovery and less comorbidity with other 
psychiatric illness, whereas patients with irritable mania or mixed states tend to respond 
better to anticonvulsants (Calabrese et al., 1996; Berghofer et al., 2008). It has therefore 
been suggested that lithium-responders have a distinct form of BPD from non-responders 
(Swann et al., 1997; Passmore et al., 2003). Some aspects of the pharmacokinetic and 
pharmacodynamic properties of lithium will be discussed, as well as the major findings of 
lithium pharmacogenetic studies.  
2.1. Lithium Pharmacokinetics 
Lithium is not metabolised and approximately 95% is renally excreted (Keck Jr and McElroy, 
2002). Lithium has a low therapeutic index, and toxicity can occur just above the therapeutic 
range, necessitating monitoring of plasma drug concentration (Keck Jr and McElroy, 2002). A 
further caution is that neurotoxicity may occur even when serum lithium levels are within 
therapeutic range. The risk for developing neurotoxicity is, however, increased due to 
additional factors, such as dehydration, systemic infection, hyperthermia, the use of other 
drugs and renal impairment (Roy et al., 1998; Lang and Davis, 2002).  
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Lithium may require six to ten days to reach steady serum concentration, as it moves slowly 
through the extracellular compartment. Its distribution in organs is near uniform and similar 
to the distribution of sodium in the body (Groleau, 1994). Following glomerular filtration 
within the kidneys, at least 70% of the drug is reabsorbed by the renal tubules, due to a 
competition of lithium with sodium in the sodium-proton antiporter (reviewed in Battle et 
al., 2008).  
The absorption of lithium into cells occurs mostly through a voltage-sensitive sodium 
channel, which has a permeability near or equal to that for sodium (Armett and Ritchie, 
1963; Vasilyev et al., 2002). Efflux occurs through sodium-lithium countertransport, the 
exact pathway of which is not clear (Sarkadi et al., 1978). Some studies, however, show that 
the pump responsible for sodium-lithium countertransport is likely to be the sodium-
hydrogen exchange protein (Serrani et al., 2000; Ng et al., 2000). 
Peak lithium levels in the brain are reached after approximately 24 hours (Chen et al., 2004). 
The half-life of lithium in the brain is 28 hours, compared to 16 hours in the serum. A high-
resolution whole brain 3D Lithium-7 magnetic resonance spectroscopy imaging (MRSI) study 
on human BPD patient brains have demonstrated that lithium is not evenly distributed 
throughout the brain, but is concentrated in specific brain regions, especially at higher 
lithium serum concentrations (Lee et al., 2012). Some of these regions are part of the 
anterior limbic network that maintains emotional homeostasis and lithium’s effectiveness 
may be due to it specifically targeting these areas (Mega et al., 1997; Strakowski et al., 
2004). 
2.2. Lithium Pharmacodynamics 
Despite numerous studies showing the effectiveness of lithium in the treatment of especially 
acute mania, the exact mechanism of lithium action has not been fully elucidated. It appears 
that the therapeutic actions of lithium involve several complex and possibly inter-related 
processes (Malhi et al., 2013). Unlike other psychotropics, lithium does not bind to cellular 
receptors, but is known to interact with many elements of second messenger systems via 
enzyme inhibition, thereby modulating processes upstream and downstream of its targets 
and modulating neurotransmission (Stahl, 2008).  Lithium appears to have neuroprotective 
properties and increases the volume of brain structures involved in emotional regulation 
(Bearden et al., 2007; Monkul et al. 2007; Hajek et al., 2013).  
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At a neuronal level it reduces excitatory, but increases inhibitory neurotransmission. It 
reduces oxidative stress caused by multiple episodes of mania and depression and increases 
the levels of protective proteins, such as brain-derived neurotrophic factor, and reduces 
apoptotic processes, thereby exerting some therapeutic action. Hypotheses regarding the 
mechanism of action of lithium include competition with magnesium, changes in expression 
of genes involved in inositol turnover and the inhibition of glycogen synthase kinase 3. 
2.2.1. Competition with magnesium 
A leading hypothesis to explain its mood-stabilising effect is that lithium competes with 
magnesium (Mg2+) for metal-binding sites in enzymes that are involved in neurotransmitter 
pathways, but not in other vital Mg2+-containing proteins. As Mg2+ is a co-factor of multiple 
enzymes this may explain several of lithium’s biochemical effects (Amari et al., 1999; Ryves 
and Harwood, 2001). 
The biochemical properties of lithium are closer to Mg2+ than to any other alkali metals in 
group IA of the periodic table of elements. Both lithium and Mg2+ are non-polarised cations, 
have high charge density and a strong affinity for “hard” O-containing ligands, as well as 
having similar ionic radii (Shannon, 1976). For lithium treatment to be effective, yet not life-
threatening, it needs to compete with Mg2+ in some, yet not in other critical proteins. Mg2+ is 
favoured above lithium in most proteins by a solvent-inaccessible Mg2+-binding site that is 
lined with negative charges e.g. Asp/Glu. There are, however, exceptions that allow the 
binding of lithium. Dudev and Lim (2011) have demonstrated that enzymes that are lithium-
sensitive have Mg2+-binding sites with a high positive charge density, some bulky ligands and 
high solvent exposure for dicationic, but not for tricationic complexes (Dudev and Lim, 
2011).  
In vitro, lithium can successfully compete with Mg2+ and bind to metal-containing sites in G-
proteins (Srinivasan et al., 2004), GSK3 (Ryves and Harwood, 2001), IMPase (Leech et al., 
1993), inositol polyphosphate phosphatase (Inhorn and Majerus, 1987), fructose-1,6-
bisphosphate (Villeret et al., 1995) and the human erythrocyte membrane (De Freitas et al., 
1994).  
2.2.2. Regulation of Ion Exchange 
The dysregulation of ion homeostasis has been reported to correlate with changes in the 
mood of bipolar patients, and some evidence points to lithium correcting this imbalance 
(Dubovsky et al., 1992; Herman et al., 2007).  
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All tissues in the body maintain a sodium electrochemical gradient that is required for a wide 
range of transport functions, e.g. glucose and amino acid uptake, ion transport and others. It 
is further essential to maintain cell excitability, to control intracellular sodium and calcium 
concentrations and intracellular pH (El-Mallakh and Jaziri, 1990; Fiekers, 2001). 
The symptoms of BPD can partly be explained by high intracellular sodium and calcium levels 
in the brain, as these result in an increase in neurotransmitter release and reduce the 
membrane potential to increase cell excitability. The intracellular sodium concentrations of 
depressed or manic BPD patients have been reported to be two to five times that of normal 
levels (Shaw, 1966; Naylor et al., 1970). It has been observed that lymphoblasts and 
lymphocytes of BPD patients have a lower capacity to respond to increased intracellular 
sodium levels (Wood et al., 1991), which is reported to involve dysregulation of Na+-K+-
ATPase expression (El-Mallakh and Wyatt, 1995). A reduction in the activity of this pump has 
been observed in patients, particularly when they are in the depressed phase, which is 
associated with an increase in sodium retention (El-Mallakh et al., 1996). A pathway-based 
analysis of GWAS studies in BPD has also revealed that the most enriched gene sets 
associated with this phenotype are ion channel structural and regulatory genes (Askland et 
al., 2009).  
Lithium, as well as other mood stabilisers, such as CBZ, VPA and LTG, reduces intracellular 
sodium and calcium concentrations, thereby non-specifically inhibiting neurotransmitter 
release (Farber et al., 2002; Hahn et al., 2004; Wasserman et al., 2004). Lithium decreases 
intracellular sodium concentrations, through two different mechanisms. Lithium can 
displace sodium on a one to one basis as it accumulates within electrically active tissues 
(Haas et al., 1975), causing a decrease in 24 hour exchangeable sodium and residual sodium 
in lithium-treated patients (Coppen et al., 1965). Long-term lithium treatment also causes an 
increase in Na+-K+-ATPase activity in erythrocyte membranes, with concurrent reduction in 
sodium and calcium in the erythrocytes of BPD patients (Hokin-Neaverson and Jefferson, 
1989). Additionally, lithium reduces N-methyl-D-aspartate (NMDA) receptor mediated Ca2+-
influx (Chuang, 2004; Ghasemi et al., 2010), further normalising intracellular calcium levels in 
BPD patients (Dubovsky et al., 1992). Lithium’s influence on sodium and calcium levels 
within the brain may play a role in the mood stabilising action of lithium in patients with 
BPD. 
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2.2.3. Lithium’s effect on Gene Expression and Activity 
Lithium is known to disrupt the activity of enzymes involved in inositol turnover and inhibits 
Glycogen synthase kinase 3 (GSK3), which suggests the potential involvement of the inositol 
and Wnt signalling pathways in lithium action (Berridge et al., 1989; Hedgepeth et al., 1997). 
Other signalling pathways, such as cyclin dependent kinase-5, protein phosphatase 1, 
protein phosphatase 2A and MEK/ERK have also been found to be regulated by lithium 
(Mora et al., 2002; Pardo et al., 2003; Jordā et al., 2005). In rodent brains, lithium treatment 
induces several changes in gene expression and is therefore thought to be involved in many 
cellular processes, although the exact neuronal processes are not completely understood 
(Fatemi et al., 2009). The main candidates to explain lithium’s mechanism of action are GSK3 
and inositol-related genes.  
2.2.3.1. Inositol phosphate depletion 
The enzyme inositol monophosphatase (IMPase) was the first identified target of lithium 
(Hallcher and Sherman, 1980). IMPase is involved in the formation of phosphatidyl inositol 
(PI) through the dephosphorylation of inositol monophosphate to release myo-inositol. 
Inositol monophosphatase is formed from inositol phosphate (IP3) through two 
dephosphorylation steps, the latter completed by inositol 1-polyphosphate phosphatase 
(IPP), a second lithium sensitive enzyme (Inhorn and Majerus, 1988).  
Due to lithium’s action on two enzymes involved in its formation, the synthesis of myo-
inositol is sensitive to lithium. Intra-cellular levels of inositol can therefore be lowered by 
lithium treatment (Harwood, 2004). In cells, inositol depletion can cause a significant change 
in inositol phosphate signalling and lithium may potentially enhance the effect, through 
additionally lowering inositol up-take (Calker and Belmaker, 2000).  
Gene expression studies on human neuronal cell lines, have identified several genes 
associated with inositol metabolism to be up- or down-regulated, following chronic lithium 
treatment (Seelan et al., 2008). Levels of IP3, a downstream product of inositol metabolism, 
are lowered by lithium. IP3 is a second messenger that binds to the endoplasmic reticulum 
releasing calcium (Ca2+) from its intracellular store (Mikoshiba et al., 1993).  The transient 
elevation of Ca2+ affects several cellular processes, including cell motility, cell survival and 
neurotransmitter release. 
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Behavioural changes due to inhibition of inositol phosphatases by lithium have been 
reported in in the social amoeba, Dictyostelium (King et al., 2009) and in Caenorhabditis 
elegans (Tanizawa et al., 2006). In mammals, however, inositol depletion does not mimic 
lithium’s effects on behaviour. In mice, for example, a heterozygous deletion of the sodium 
dependent myo-inositol cotransporter-1 (SMIT-1) reduces myo-inositol levels to the same 
degree as lithium, but has no effect on behavioural phenotypes affected by lithium 
(Shaldubina et al., 2006).  
2.2.3.2. Glycogen synthase kinase 3 
The GSK3 serine threonine kinases family, composed of two isoenzymes GSK3A and GSK3B, 
have several biological roles including implications in the regulation of development, 
immunity/inflammation, cancer and several aspects of neuronal function (Cohen and Frame, 
2001; Woodgett, 2001; Kaidanovich-Beilin and Woodgett, 2011). Dysregulation of GSK3 has 
understandably been associated with a number of clinical conditions, such as diabetes, 
oncogenesis and neurodegeneration. 
Lithium inhibits GSK3, both directly and indirectly. Lithium firstly acts as a non-competitive 
inhibitor of the binding of Mg2+, a co-factor of GSK3 (Ryves and Harwood, 2001); and further 
affects GSK3 by activation of the serine/threonine kinase, AKT, resulting in an increase of 
GSK3 phosphorylation on the Ser 9 residue and consequent inactivation in cultured neurons 
(Chalecka-Franaszek and Chuang, 1999). In rodents, the inhibition of GSK3 activity could 
mimic both the “antidepressant” and “antimanic” effects of lithium (Beaulieu et al., 2004). 
GSK3 has several substrates and its inhibition by lithium, therefore has a resultant effect on 
many different pathways with myriad downstream effects. The regulation of GSK3 by lithium 
and its effect on gene expression, synaptic plasticity, and neurogenesis, which in turn 
regulate mood-related behaviours, is demonstrated in Figure 2.1 (Li and Jope, 2010). 
Lithium’s inhibition of GSK3 can mediate its mood-stabilising effect through upregulation of 
cyclic AMP (cAMP) response element-binding protein (CREB) (Mai et al., 2002), the over-
expression of which has an antidepressant-like effect in the dentate gyrus (Chen et al., 
2001). GSK3B has been implicated in the regulation of the direction and magnitude of N-
methyl-D-aspartate receptor (NMDAR) dependent plasticity at excitatory synapses (Peineau 
et al., 2007; Hooper et al., 2007). GSK3B further regulates a large group of transcription 
factors and transcriptional modulators and could therefore be responsible for the regulation 
of the expression of genes, involved in mood disorders and mood regulation (Shaltiel et al., 
2007).  
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In addition to its role in the activation of neuroprotective neurotrophins, such as brain-
derived neurotrophic factor (BDNF), the inhibition of GSK3 is known to have intracellular 
neuroprotective actions. GSK3 inhibitors can reduce many types of apoptosis-inducing 
insults, such as misfolded protein accumulation and DNA damage (Song et al., 2002; 
Watcharasit et al., 2002).  
 
Figure 2.1: Illustration of regulation of GSK3 by lithium via signalling pathways and 
functions of GSK3 inhibition in mood regulation.  GSK3 is regulated by BDNF, serotonin, and 
dopamine through the Akt signalling pathway, Wnt signalling and by the NMDA receptor 
through protein phosphatases. GSK3 affects gene expression, synaptic plasticity, and 
neurogenesis, which in turn regulate mood-related behaviours. Abbreviations: α,β, γ: G-
protein subunits; β-arr: β-arrestin; BD: bipolar disorder; BDNF: brain-derived neurotrophic 
factor; DA: dopamine; D2: type 2 dopamine receptor; DISC1: disrupted in schizophrenia 1; 
GSK3: glycogen synthase kinase-3; 5HT: serotonin; 5HT1A, 1B, 2A: serotonin receptor 
subtypes; LTD: long term depression; NMDA: N-methyl-D-aspartic acid; P: phosphorylated; 
PDK1: phosphoinositide-dependent kinase-1; PI3K: phosphatidylinositol-3-kinase; PP1, PP2A, 
PP2B: protein phosphatase 1, 2A, and 2B; TF: transcription factors; TrKB: type B 
tropomyosin-receptor-kinase; YMRS: Young Mania Rating Scale (Image from Li and Jope, 
2010). 
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Neuroprotection helps cells to respond better to stress, as well as enhancing neuronal 
functions that could counteract some stress-induced mood changes. GSK3 inhibits the 
transcription factor HSF-1, which causes a reduction in the expression of chaperone proteins 
(Chu et al., 1996). Chaperone proteins provide protection against neuronal insults, and the 
inhibition of GSK3 by lithium leads to an upregulation in expression of these chaperones, 
thereby strengthening cellular responses to stress. GSK3 also promotes impairments 
associated with DNA damage, such as in the nonhomologous end-joining DNA repair 
pathway, which is promoted by GSK3 inhibition (Yang et al., 2009). 
GSK3 plays a major role in regulating the innate and adaptive immune responses, which has 
an important influence on particularly the pathology and treatment of depression (Miller et 
al., 2009). GSK3 inhibition by lithium leads to a reduction of several pro-inflammatory 
cytokines and, conversely, an increase in the levels of the anti-inflammatory cytokine, IL-10, 
which was demonstrated to rescue approximately 70% of investigated mice from an 
otherwise lethal inflammatory response to lipopolysaccharides (Martin et al., 2005).  
Lithium is also able to slow the abnormally fast circadian rhythms found in many bipolar 
patients (Welsh and Moore-Ede, 1990; Klemfuss, 1992; Hafen and Wollnik, 1994; Abe et al., 
2000; Dokucu et al., 2005), which is possibly mediated by GSK3B. GSK3B can modify several 
clock genes and has been implicated in the regulation of the stability and/or nuclear 
translocation of PER2, CRY2, CLOCK, REV-ERBa and BMAL1 (Harada et al., 2005; Yin et al., 
2006; Spengler et al., 2009; Ko et al., 2010; Sahar et al., 2010).  
In addition, GSK3 is an essential element of the Wnt/beta-catenin pathway critical for 
patterning, cell fate specification, and stem cell regulation during the development of many 
tissues and organs, including the mammalian brain (reviewed by Kim and Snider, 2011). In 
adults, Wnt signalling regulates stem cell homeostasis and cell proliferation, thereby 
continuing to influence the maintenance and regeneration of many tissues (reviewed by 
Wend et al., 2010). In the brain, Wnt signalling is especially important as it regulates neurite 
outgrowth, axon remodelling, synapse formation and plasticity, and neurogenesis – 
processes critical for normal brain function (Budnik and Salinas, 2011).   
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2.2.4. Pharmacogenetic studies on lithium response 
Pharmacogenetic studies on lithium response have focused on the pharmacodynamic 
aspects of the drug, due to the lack of empirical evidence for a relationship between plasma 
drug levels and lithium efficacy. Linkage studies, candidate gene studies, GWAS and gene 
expression studies have been performed to identify genetic determinants of lithium 
treatment response, thorough reviews of which have been conducted elsewhere (McCarthy 
et al., 2010; Smith et al., 2010; Rybakowski et al., 2013a) 
Several candidate gene studies on lithium response have been performed on inositol-related 
genes, such as PLCG1, a gene coding for phospholipase cy1, a key enzyme involved in the 
inositol pathway, as well as G protein-mediated signals. An association has been reported 
for a dinucleotide repeat in PLCG1 with excellent response to lithium (Turecki et al., 1998), 
although these findings were not replicated in a sample of Norwegian lithium-treated 
bipolar patients (Løvlie et al., 2001). 
Studies investigating other elements of the inositol pathway have reported association for 
the silent variant C937A in the gene inositol polyphosphate 1-phosphatase (INPP1) and 
response to lithium (Steeir et al., 1998), but this association was not replicated in other 
studies (Michelon et al., 2006). No association with lithium response has been reported for 
variants in inositol monophosphatase 1 (IMPA1) (Calabrese et al., 1996). 
Lithium is known to regulate the expression of neurotransmitters and elements of these 
systems, such as the BDNF/TrkB signalling pathway which has been studied for its 
involvement in lithium response and BPD. An association has been reported for SNP rs6265 
(Val66Met) in the BDNF gene and better response to lithium (Rybakowski et al., 2007). A 
recent study has additionally shown lithium treatment to be associated with a significant 
reduction of DNA methylation in the promoter region of the BDNF gene when compared to 
other drugs (D'Addario et al., 2012). An association with a polymorphism in the Src-family 
tyrosine kinases (FYN) gene and lithium response has also been reported. FYN belongs to a 
family of protein kinases that phosphorylates the NMDA receptor subunits that play a role in 
regulating the BDNF/TrkB signal transduction pathway (Szczepankiewicz et al., 2009). 
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Lithium is known to the upregulate cAMP response element-binding protein (CREB) (Mai et 
al., 2002) and genetic variation in genes coding for CREB proteins have therefore been 
investigated for a role in determining response to lithium prophylaxis (Mamdani et al., 
2008). Mamdani and colleagues (2008) reported the SNPs rs6740584 and rs2551640 in 
CREB1 to be associated with response to lithium. 
Serotonin- and dopamine-related genes have also been investigated; associations with 
lithium response and variants in the serotonin transporter gene (5’-HTTLPR), tryptophan 
hydroxylase (TPH) and dopamine receptor D1 (DRD1) have been found (Serretti et al., 1999; 
Rybakowski et al., 2005; Rybakowski et al., 2009).  
Only one GWAS study for lithium response in bipolar patients has been published to date 
and no SNP met the threshold for genome-wide association (Perlis et al., 2009). However, 
five regions showed consistent evidence of association in a second cohort of patients 
treated with lithium (Perlis et al., 2009). One of these regions includes the gene coding for a 
subunit of the ionotropic glutamate receptor gene, GLuR2/GLURB, which binds to alpha-
amino-3-hydroxy-5-methyl-4-isoxazolpropionate (AMPA). This gene, GRIA2 (glutamate/ 
AMPA receptor), is also downregulated by chronic lithium treatment in human neuronal cell 
lines (Seelan et al., 2008).  
In 2008, the Consortium on Lithium Genetics (ConLiGen, www.conligen.org) was created. 
This is an international joint effort, with sample size currently comprising of more than a 
1200 patients, characterised for response to lithium using a stringent phenotype definition 
(Schulze et al., 2010). The scale used to determine phenotype quantiﬁes the degree of 
improvement over the duration of treatment with a score from 0 to 10, where patients with 
a total score of seven or above are considered full responders (Manchia et al., 2013). 
ConLiGen aims to assess all aspects of lithium pharmacogenetics, including genetic 
susceptibility to potential adverse effects due to treatment. The first objective of the project 
will be to conduct a GWAS of response to lithium treatment in bipolar disorder. Preliminary 
reports from this study suggest the possible involvement of SLC4A10, the sodium lithium 
bicarbonate transporter gene, in lithium response (Rybakowski, 2013a). 
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Chapter 3. Lithium-induced Adverse Drug Reactions 
It is evident that lithium influences multiple pathways that are often interconnected and can 
have an infinite number of effects on neuronal as well as other systems within the human 
body. The current disease model of BPD is that it is a complex polygenic disorder with high 
heterogeneity. Not all patients will, therefore, have the exact same underlying combination 
of genes or pathways involved in their disease. When a drug such as lithium acts on multiple 
systems, it will have off-target effects leading to ADRs. 
Non-adherence to lithium treatment, the main cause of which is ADRs, is one of the major 
factors that lower its effectiveness in clinical practice (Maj et al., 1998; Schumann et al., 
1999). Approximately 75%-90% of patients on long-term lithium treatment experience one 
or more ADRs (Dunner, 2000). The multiple ADRs of lithium use include thyroid dysfunction, 
neurological, gastrointestinal, metabolic, dermatological, nephrogenic, cognitive and sexual 
side effects (reviewed by Dols et al., 2013). Combating these side effects could therefore be 
an important factor in improving the persistence on lithium treatment. Attempts at 
pharmacogenetically determining factors associated with the development of one or more 
of these ADRs, could provide clues for ways of effectively treating the ADRs, as well as 
improving our understanding of mechanisms of action of this drug.  
Due to interindividual differences in PGx, lithium dose is not a good predictor of its 
effectiveness or the risk of developing ADRs. There is, however, a positive correlation 
between lithium serum levels and the occurrence and severity of ADRs (Wilting et al., 2009). 
The monitoring of lithium serum levels is, therefore, currently not only critical to prevent the 
development of lithium toxicity, but also to prevent ADRs. Lithium serum levels are advised 
to remain at 0.6-0.8mmol/L for maintenance treatment and at 0.8-1.2mmol/L for the 
treatment of acute manic episodes (Amdisen, 1977). 
To date, no studies have been conducted on the prevalence of lithium ADRs in a South 
African population. There is, however, some evidence that there may be inter-population 
differences in the frequency of ADR occurrence. For example, African Americans have been 
reported to have a higher prevalence of ADRs than their Caucasian counterparts in the 
United States, even when lithium is within the therapeutic range (Strickland et al., 1995). 
This may be due to the higher red blood cell to plasma ratio of lithium in African Americans 
when compared to Caucasians (Strickland et al., 1995) or Asians (Okpaku et al., 1980).  
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3.1. Nephrogenic side effects 
Two of the most common ADRs in lithium-treated patients are polydipsia (increased thirst) 
and polyuria (increased urinary volume), which are largely due to lithium’s effect within the 
kidneys. Patients on long term lithium treatment often have an irreversible reduction in 
maximal urinary concentrating ability, which could lead to nephrogenic diabetes insipidus 
(NDI). NDI is characterized by increased water and sodium diuresis, resulting in mild 
dehydration, hyperchloremic metabolic acidosis and renal tubular acidosis. There is a risk of 
developing hypernatraemic dehydration if the patient is unable to drink, which is a particular 
risk factor in the elderly (Mukhopadhyay et al., 2001). The risk of developing NDI correlates 
with the duration of lithium therapy and this may occur as early as 8 weeks after treatment 
initiation and be present in 10-40% of patients (Bendz and Aurell, 1999).  In patients treated 
long term, NDI is only partly reversible when lithium treatment is stopped, suggesting some 
permanent renal damage. 
 
In the kidney, lithium is freely filtered through the glomeruli and nearly 80% is reabsorbed in 
the renal proximal tubule and a small fraction in the distal parts of the nephron through the 
epithelial sodium channel (ENaC). The ENaC is permeable only to lithium and sodium, with 
its permeability to lithium being 1.5-2 fold higher than for sodium (Grünfeld and Rossier, 
2009). Sodium is exported from the interior of the cells into the blood by the sodium-
potassium-transporting ATPase (Na+-K+-ATPase) pump, for which lithium is a poor substrate 
(Grünfeld and Rossier, 2009). Lithium-induced NDI can be treated with amiloride, a blocker 
of ENaC (Grünfeld and Rossier, 2009). The transport of sodium, potassium and water in a cell 
of the cortical collecting duct of the kidney under basal conditions compared to in the 
presence of lithium is demonstrated in Figure 3.1. 
Lithium can accumulate intracellularly in the collecting duct where the inhibition of the 
GSK3B enzyme by lithium (section 2.2.3.2) leads to dysregulation in water and sodium 
transport. Subsequently, the cell becomes insensitive to aldosterone and vasopressin 
actions, resulting in water and sodium diuresis (Decloedt and Maartens, 2011). Lithium also 
causes dysregulation in the expression and trafficking of the aquaporin 2 (AQP2) water 
channel along the entire collecting duct, which might be related to a decrease in interstitial 
osmolarity. Mutations in AQP2 causes inherited NDI and this protein therefore has an 
important role in renal physiology. Cellular levels of AQP2 were observed to be reduced by 
lithium (Oksche and Rosenthal, 1998) through the reduction of AQP2 mRNA levels (Laursen 
et al., 2004).  
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AQP2 down-regulation in rat collecting ducts was observed after only four weeks of lithium 
treatment, which was only partly reversed with withdrawal of lithium (Mønster et al., 2004). 
The downregulation of AQP2 is influenced by the inhibition of GSK3B and the subsequent 
inhibition in cAMP recruitment of AQP2. A study of the inner medullary collecting ducts of 
lithium-treated rats demonstrated that components of several signalling pathways, including 
protein kinase B (AKT) (section 3.7.2) and mitogen- activated protein kinases, are activated 
by lithium treatment in the kidney (Li et al., 2006).  
 
Figure 3.1: The transport of sodium, potassium and water in a cell of the cortical collecting 
duct of the kidney under basal conditions compared to in the presence of lithium. a) Under 
basal conditions sodium enters the cell through ENaC along an electrochemical gradient and 
it is actively transported by the Na+-K+-ATPase pump. Potassium enters the cell through Na+-
K+-ATPase and is secreted through rOMK, along the electrochemical gradient created by the 
entry of sodium.   Water enters the cell through AQP2 and exits through AQP3 and AQP4. 
The transport of sodium and water is controlled by the hormones, aldosterone and 
vasopressin. b) During lithium treatment, lithium enters the cell through ENaC, preventing 
the entry of sodium. As the Na+-K+-ATPase pump is impermeable to lithium, lithium 
accumulates in the cell and inhibits GSK3B, which affects the levels of AQP2 and ENaC. The 
cell becomes partially insensitive to aldosterone and vasopressin action and lithium 
therefore leads to water and sodium dysregulation in the kidneys (Image from Grünfeld and 
Rossier, 2009). 
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A more concerning side effect of long-term lithium treatment is chronic tubulointerstitial 
nephropathy, which is characterised by decreased glomerular filtration rate and chronic 
kidney disease. Interstitial fibrosis can present as early as five years after treatment initiation 
and may develop chronically in the absence of episodes of lithium intoxication (Presne et al., 
2003), and can further lead to the development of end-stage renal disease. In a recent meta-
analysis the absolute risk of developing renal failure was only 0.5% (McKnight et al., 2012).  
Lithium-induced nephropathy can be detected by testing for elevated serum creatinine 
measurements, but patients that are efficiently managed with lithium are often not regularly 
followed-up, and renal failure is, therefore, often detected too late. The practice guidelines 
of the American Psychiatric Association recommend measurement of serum creatinine level 
every 2–3 months during the first 6 months of lithium therapy and every year thereafter 
(Alexander et al., 2007). Patients in rural areas are often not treated with lithium at all, in 
spite of it being the first-line treatment in BPD, due to fears of them developing renal failure 
without access to clinics for regular monitoring of creatinine levels. This is particularly 
pertinent to settings such as in South Africa and the rest of the African continent. 
3.2. Dermatological side effects 
Lithium-induced dermatological side effects were first described in the late 1960’s (Callaway 
et al., 1968).  Various skin problems associated with lithium use, including psoriasis, 
acneiform eruption, exfoliative dermatitis, pityriasis, versicolour, pruritic maculopapular 
erythematous eruption, dermatitis herpetiformis and Darier’s disease have since been 
reported (Heng, 1982; Jenni and Krebs, 1984; Rubin, 1995). The reported prevalence of 
these dermatological side effects vary from 3.4 to 45% among lithium-treated patients 
(Jafferany, 2008), with the most common symptoms being acne vulgaris and psoriasis (Chan 
et al., 2000). In contrast with acute lithium toxicity, most dermatological side effects occur at 
therapeutic serum lithium levels and it can have a dramatic effect on patient compliance 
(Chan et al., 2000).  
The mechanism by which lithium causes various dermatological side effects is unknown, 
although these side effects are commonly associated with pathologic findings of neutrophilic 
infiltration in the epidermis. Lithium’s effect on G-proteins, its inhibition of adenyl cyclase 
and inositol monophosphatase (leading to lower cAMP and inositol levels), coupled with the 
inhibition of GSK3 have been proposed to lead to neutrophilia, and the consequent potential 
development of dermatoses (Jafferany, 2008).  
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Decreased cAMP has been proposed to lead to keratinocyte proliferation, increased 
chemotaxis and phagocytic activity. These factors are all commonly involved in in the 
pathogenesis of acneiform eruptions, psoriasiform eruption, pustular psoriasis, and other 
conditions characterized by neutrophilic infiltration. Lithium can cause dermatological 
diseases both de novo and through the exacerbation of pre-existing conditions.  
Psoriasis can possibly be caused or exacerbated by the decreased inositol levels in the skin 
caused by lithium. Inositol depletion leads to the inhibition of calcium release and calcium 
levels are important in the process of keratinocyte differentiation and proliferation. Psoriatic 
keratinocytes do not undergo complete differentiation and lack the elevated intracellular 
calcium levels necessary for terminal differentiation (Hwang et al., 2001). In support of this 
theory, Grisaru and Belmaker (1994) published a report of a patient with lithium-
exacerbated psoriasis that was dramatically improved by peripheral inositol 
supplementation (Grisaru and Belmaker, 1994). Once the daily dose of inositol was 
removed, the psoriasis worsened, but improved again upon the reapplication of inositol. 
Peripheral inositol is available in peripheral tissue, such as the skin, but does not cross the 
blood-brain barrier and, therefore, do not alter lithium’s effect on the brain (Allan et al., 
2004). Similarly, a double-blind, randomized, placebo-controlled, crossover trial found a 
significant improvement in the psoriasis of patients on lithium receiving an inositol 
supplement compared to patients receiving a placebo (Allan et al., 2004). 
3.3. Metabolic effects 
Weight gain is common among patients with BPD, with overweight and obesity ranging from 
20% to 35%, exceeding the prevalence in the general population (McElroy et al., 2002; 
Fagiolini et al., 2002; McElroy et al., 2004). At a Bipolar Disorder centre in Pennsylvania, 49% 
of patients had abdominal obesity and 30% displayed metabolic syndrome (Fagiolini et al., 
2005). Metabolic syndrome is especially dangerous as it is associated with other clinical 
conditions, including insulin resistance, dyslipidaemia, central obesity, hypertension, 
impaired glucose tolerance and high rates of atherosclerotic disease (Toalson et al., 2004). 
Weight gain is an adverse effect of several psychiatric drugs used in the treatment of BPD. In 
addition to medication, weight gain in BPD patients can also be influenced by atypical 
depression, comorbid eating disorders or merely disturbed eating habits (Torrent et al., 
2004; Wildes et al., 2006).  
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Treatment-induced weight gain can occur in a short period after treatment commencement 
and patients therefore develop a negative view of the treatment, which often negatively 
impacts treatment compliance – even in patients experiencing an amelioration of their 
affective symptoms. In patients on lithium prophylaxis, weight gain was related to poor 
compliance in up to 50% of cases, and 90% of cases considered treatment discontinuation 
(Goodwin and Jamison, 2007).   
Weight gain is reported to be present in 25% of patients on lithium treatment (Goodwin and 
Jamison, 2007) and one study has suggested that over 30% of lithium-treated patients are 
obese (Silverstone and Romans, 1996). Weight gain has been found to increase in the first 1-
2 years of treatment and then remain constant (Vestergaard et al., 1988). It can be explained 
by fluid retention, increased appetite, lithium-related subclinical hypothyroidism or a 
combination of these factors (reviewed by Torrent et al., 2008). In addition, lithium may 
affect carbohydrate metabolism, through insulin-like activity, leading to increased glucose 
absorption in adipose tissue (Shopsin et al., 1972; Müller-Oerlinghausen et al., 1979). 
Another potential factor is polydipsia (increased thirst), which can cause some patients to 
drink large quantities of high-caloric drinks, as shown in a study of weight gain in patients 
with BPD (Elmslie et al., 2001). Lastly, it has been reported that lithium may have a direct 
effect on the hypothalamus to stimulate appetite and thirst (Kulkarni and Kaur, 2001). 
3.4. Endocrine side effects 
Lithium is associated with the development of hypothyroidism by affecting the thyroid gland 
function. The prevalence of hypothyroidism is as high as 47% in patients taking lithium, with 
females being five times more at risk than males (Esposito et al., 1997; Henry, 2002). The 
lithium ion is concentrated in the thyroid gland where it interferes with the production of 
thyroid hormones (TH). Lithium inhibits iodine uptake, as well as altering thyroglobulin 
structure. TH secretion is also inhibited by lithium, possibly through its interference with 
tubulin polymerisation (Burrow et al., 1971; Bhattacharyya and Wolff, 1976). Subclinical 
hypothyroidism is present in 8% of females and 3% of the general male population, and 
these patients are at increased risk for developing hypothyroidism on lithium.  
Lithium-induced reduction in TH release, results in a reduction in feedback inhibition upon 
the pituitary and consequent increase in thyroid stimulating hormone (TSH) secretion 
(Schiemann and Hengst, 2002). A goitre (swelling of the thyroid gland) can develop within 
weeks or only after several years of lithium treatment and occurs in 5% to 55% of patients 
treated with lithium (Kibirige et al., 2013).  
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The large variation in reported frequency can be explained by differences in iodine content 
in the geographical study settings, the duration of lithium use and different study designs. In 
addition, lithium is known to induce a spectrum of calcium homeostasis disorders, including 
cases of overt hyperparathyroidism (HPT) and cases of hypercalcemia without elevated 
parathyroid hormone (PTH) levels or elevated PTH without hypercalcemia (Nordenstrom et 
al., 1994; Komatsu et al., 1995). The prevalence of lithium-associated HPT is estimated to 
range from 4.3% (Awad et al., 2003) to 6.3% (Bendz et al., 1996), which is higher than the 
overall prevalence of HPT in the general population (1–4/1000) (Melton, 1991).  
3.5. Neurological side effects 
Tremor is a frequent side effect of lithium and occurs in 4% to 65% of patients, with a recent 
review estimating the average percentage at 27% (Gelenberg and Jefferson, 1995). Tremor 
has an influence on patient compliance and in one study 32% of patients reported lithium 
tremor to result in some disability and non-compliance (Morgan and Sethi, 2005). Severe 
tremor can be one of the first signs of lithium toxicity. 
The pathophysiology of lithium tremor has, surprisingly, never been studied (Baek et al., 
2013), but it is thought to arise from the central nervous system (Elble, 1996; Deuschl et al., 
2011) as lithium affects neural plasticity (Soeiro‐de‐Souza et al., 2012). Physiological tremor 
is reported to result from a central oscillator, originating in the inferior olive (Lamarre, 1979) 
or thalamus (Semba et al., 1980) and transmitted through the corticospinal tract (Köster et 
al., 1998).  
Lithium tremor is thought to be influenced by changes in brainstem serotonergic neurons, 
due to the negative synergistic effect in patients that are treated with other pro-
serotonergic agents, such as antidepressants (Elble, 1996). Lithium’s effects on grey matter 
volume (Monkul et al., 2007) and the microstructure of white matter (Benedetti et al., 2012) 
may additionally affect the corticospinal tract and central oscillator transmission.  
3.6. Other side effects 
Gastrointestinal side effects, such as nausea, vomiting, and diarrhoea are common, although 
generally transient, side effects of lithium treatment (Bowden et al., 2000), occurring in up 
to 50% of patients. These side effects can be symptoms of lithium toxicity, but are often due 
to excessive dosage levels in the lithium-naïve (Macritchie and Young, 2004).  
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Poorer cognitive performance is a common impairment in BPD patients, independent of 
treatment (Martinez-Aran et al., 2005; Young et al., 2006). Lithium therapy has been 
associated with poorer performance on tests of memory and motor speed (Pachet and 
Wisniewski, 2003), although these negative effects on cognition appears to be minor (Wingo 
et al., 2009).  
3.7. Candidate genes 
Although not previously investigated, we propose that lithium pharmacogenetics may play a 
role in interindividual susceptibility to lithium-related ADRs. Determining genetic factors 
associated with susceptibility to side effects, may aid in optimising prescription of lithium in 
Bipolar Disorder, as other first or second-line treatments could be prescribed for individuals 
with a high susceptibility to serious lithium-related side effects, or these could be monitored 
more carefully. Table 3.1 gives a summary of candidate genes and SNPs in these genes that 
will be investigated. 
3.7.1. Glycogen Synthase Kinase 3 Beta (GSK3B) 
The first candidate gene to be investigated for its potential role in lithium-induced side 
effects, GSK3B, has been discussed in detail in section 2.2.3.2.  
Three SNPs in GSK3B will be genotyped in the patient cohort. The first SNP, rs334558, is 
located in the promoter region and influences expression of the gene as the T allele has a 
greater transcriptional strength than the C allele (Kwok et al., 2005). This variant has been 
associated with response to lithium (Benedetti et al., 2005; Lin et al., 2012). Lithium-treated 
patients homozygous for the C allele of this variant have also been reported to have better 
renal concentrating ability than carriers of the T allele, and may therefore be more resilient 
to lithium GSK3B inhibition in the kidneys (Rybakowski et al., 2013b).The SNP, rs3755557, is 
in the promoter region and functional assays have demonstrated it to influence the binding 
affinities of transcription factors, resulting in the risk allele having a higher promoter activity 
(Kwok et al., 2005; Li et al., 2011).The third SNP, rs6438552, located in intron 5, influences 
GSK3B alternative splicing.  GSK3B has two alternatively spliced exons (9 and 11) that are 
predicted to generate four different splice isoforms (Schaffer et al., 2003). The T allele of 
rs6438552 results in greater levels of the GSK3B exon9+11 isoform and increased enzyme 
activity in lymphocytes (Kwok et al., 2005).  
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Table 3.1: Candidate genes and respective SNPs to be investigated for association with 
lithium-induced side effects 
HGVS: Human Genome Variation Society 
  
Gene Chromosomal 
Location 
NCBI 
RefSNP ID 
HGVS name SNP 
location 
Protein 
GSK3B 3q13 rs334558 NM_001146156.1: 
c.-983-18T>C 
Promoter  
rs3755557 NM_001146156.1: 
c.-983-1693A>T 
Promoter  
rs6438552 NM_001146156.1: 
c.609-157T>C 
Intron 5  
AKT1 14q32 rs10138227 NM_005163.2:        
c.-322G>A 
Promoter  
  rs1130233 NM_005163.2: 
c.726G>A 
Exon 9 Glu242= 
ARRB2 17p13 rs34230287 NM_004313.3:       
c.-228-159C>T 
Promoter  
rs1045280 NM_004313.3: 
c.840C>T 
Exon 11 Ser280= 
GRIA2 4q32 rs4302506 NM_000826.3: 
c.687T>C 
Exon 5 His229= 
PPARGC1a 4p15 rs2279525 NM_013261.3: 
c.*3193A>G  
5’UTR  
rs8192678 NM_013261.3: 
c.1444G>A 
Exon 8 Gly482Ser 
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3.7.2. V-akt murine thymoma viral oncogene homolog 1 (AKT1) and β-arrestin 2 
(ARRB2) 
AKT1 is one of three closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) 
called the AKT kinase, also known as Protein Kinase B. Activation of Akt has been found in 
the striatum, frontal cortex, and hippocampus of rodents following either acute or chronic 
treatment with lithium (Beaulieu et al., 2004). AKT1 has an important function in cell growth, 
differentiation, plasticity, as well as several key neurodevelopmental pathways (Lai et al., 
2006). Polymorphisms in AKT1 have been associated with schizophrenia (Thiselton et al., 
2008; Norton et al., 2007) and frontostriatal mediated cognitive task performance (Tan et 
al., 2008). 
β-arrestin 2 (ARRB2) is one of the arrestin proteins that were first described for their role in 
desensitizing G-protein-coupled receptors (GPCRs). β-arrestin 2 is involved in cell 
communication and signal transduction and has previously been associated with 
schizophrenia (Liou et al., 2008). The ARRB2 gene is down-regulated by lithium (Fatemi et 
al., 2009).  
AKT and ARRB2, together with protein phosphatase 2A (PP2A) form a signalling complex 
which is dissociated in response to therapeutic levels of lithium treatment. This complex is 
formed following stimulation of the dopamine D2 receptor (DRD2) and its formation leads to 
the dephosphorylation and inactivation of AKT (Beaulieu et al., 2005). In mice lacking Arrb2, 
in which this signalling complex cannot be formed, lithium treatment failed to activate Akt 
and phosphorylate GSK3 (Beaulieu et al., 2008). A model of this inhibition, as described by 
Beaulieu and colleagues (2008) is demonstrated in Figure 3.2. Furthermore, lithium also 
failed to regulate GSK3 phosphorylation in mice with reduced Akt1 activity (Pan et al., 2011). 
Disruption of the complex by lithium leads to AKT activation, increase of GSK3 
phosphorylation on the Ser9 residue and consequent inactivation of GSK3 in cultured 
neurons (Chalecka-Franaszek and Chuang, 1999). 
The mechanism of lithium’s interference with the formation of the Akt:ARRB2:PP2A 
signalling complex is not fully understood. However, in vitro experiments suggest that Mg2+ 
is required for the interaction of Akt and ARRB2 and, consequently, the formation of the 
complex, suggesting the role of lithium-Mg2+ competition (Beaulieu et al., 2008).  
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Due to both the crucial role of this complex in lithium’s inhibition of GSK3, as well as the 
important functions of these genes within the brain, polymorphisms in AKT1 and ARRB2 may 
lead to interindividual differences in patient response. The SNPs rs1130233 and rs10138227 
in AKT1 and rs1045280 and rs34230287 in ARRB2 will be investigated.  
The AKT1 variant rs1130233 is a synonymous variant that has been linked to differential 
AKT1 protein expression levels (Harris et al., 2005; Tan et al., 2008). In one study, patients 
who carried the risk allele had smaller cognitive changes than non-risk allele carrier patients 
when treated with lithium (Tan et al., 2011).  The SNP rs10138227 is located in the 5’UTR 
promoter region of AKT1 and could therefore likewise have an effect on the expression of 
AKT1. 
The SNP rs34230287, located in the promoter, modulates ARRB2 gene transcription and has 
been associated with response to methadone treatment (a drug used to treat opioid 
dependency) (Zhang et al., 2007; Oneda et al., 2010). The polymorphism rs1045280 is a 
synonymous SNP and has been associated with the development of Tardive dyskinesia (TD) 
in patients with schizophrenia (Liou et al., 2008). 
Figure 3.2: A model for the indirect 
inhibition of GSK3B activity. 
(A)Under normal conditions, Akt is 
phosphorylated and activated 
leading to the phosphorylation and 
inhibition of GSK3B.  Equilibrium is 
maintained between Akt 
phosphorylation/activation (by 
PI3K/PDK1) and its inactivation. Akt 
inactivation/dephosphorylation is 
facilitated by the formation of a 
signaling complex whereby bArr2 
scaffolds Akt and PP2A in response 
to stimulation of GPCRs, such as the 
D2 DA receptor. 
(B) Lithium destabilizes the signaling 
complex formed by Akt, bArr2, and 
PP2A, thereby enhancing Akt activity 
by reducing its dephosphorylation. 
In turn, increased Akt activity results 
in a greater inhibition of GSK3B.  
(Figure adapted from Beaulieu et al., 
2008) 
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3.7.3. Glutamate receptor, ionotropic, AMPA 2 (GRIA2) 
Glutamate receptor, ionotropic, AMPA 2 (GRIA2) is one of a family of glutamate receptors 
that are sensitive to alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), and 
function as ligand-activated cation channels. AMPA receptors mediate fast excitation in the 
CNS and play a key role in hippocampal synaptic long-term potentiation (LTP) and 
depression (LTD) (Din et al., 2010). These channels are assembled from four related 
subunits, GRIA1-4.  GRIA2 is essential for the channel to be permeable to calcium. 
GRIA2 encodes for GLUR2 subunits and is located on chromosome 4q32-33. This region has 
previously been associated with BPD and schizophrenia (Ekholm et al., 2003; McInnis et al., 
2003). GRIA2 is down-regulated by chronic lithium treatment in human neuronal cell lines 
(Seelan et al., 2008) and chronic lithium treatment decreases the levels of GluR2 in 
hippocampal neurons (Du et al., 2008). SNPs in the region in which GRIA2 is located, showed 
the strongest association with lithium response in a GWAS study, although genome-wide 
significance was not reached (Perlis et al., 2009). A SNP in GRIA2, rs3813296, has been 
associated with improvement in PANSS negative scores, a measure of response to 
antipsychotics (Crisafulli et al., 2012). In this study the synonymous SNP, rs4302506, will be 
investigated. This SNP has previously been investigated for association with BPD (Chiesa et 
al., 2012a), response to antipsychotics (Crisafulli et al., 2012), as well as response to 
treatment in major depressive disorder (MDD) (Chiesa et al., 2012b). An association was 
found between rs4303506 and age of onset of depression (Chiesa et al., 2012b). 
3.7.4. Peroxisome proliferator-activated receptor gamma, co-activator 1 alpha 
(PPARGC1a) 
Peroxisome proliferator-activated receptor (PPAR) gamma, co-activator 1 alpha (PPARGC1a) 
is located on chromosome 4p15 and encodes for a transcriptional co-activator, PGC-1α, 
which regulates genes involved in energy metabolism. PGC-1 α, can interact with and 
regulate CREB, as well as increasing the transcriptional activity of thyroid hormone receptor 
and several nuclear receptors, including PPAR-α and PPAR-γ. Through the action of its 
targets it regulates mitochondrial function, oxidative stress, gluconeogenesis and lipogenesis 
(Puigserver et al., 1998; Wu et al., 1999; Herzig et al., 2001; Puigserver and Spiegelman, 
2003). 
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Lithium treatment inhibits PPARGC1a expression in human neuronal cell lines (Seelan et al., 
2008) and to almost undetectable levels in brown preadipocytes during brown fat 
differentiation. This could explain disturbances in adipose tissue accumulation and weight 
gain experienced by patients on lithium treatment (Rodr  guez de la Concepci n et al., 2005).  
The first polymorphism in PPARGC1a to be investigated is the common nonsynonymous 
Gly482Ser polymorphism, rs8192678. This SNP has been associated with obesity 
(Ridderstråle et al., 2006), weight gain (Deeb and Brunzell, 2009), type 2 diabetes mellitus 
(Kunej et al., 2004; Barroso et al., 2006; Yang et al., 2011), non-alcoholic fatty liver disease 
(Yoneda et al., 2008) and insulin sensitivity (Stefan et al., 2007) amongst other phenotypes. 
The second SNP to be investigated, rs2279525, is located in the 5’ UTR of PPARGC1a and 
may influence protein expression, although the exact function is unknown. 
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3.8. Aim of this study 
The aim of this pilot study was to identify suitable candidate genes and investigate variants 
in these genes for association with interindividual susceptibility to developing side effects on 
lithium treatment in a South African cohort of BPD type I patients.  
Objectives: 
 To collect data regarding twenty of the most common side effects reported in 
lithium-treated BPD type I patients 
 To genotype the cohort for variants in the candidate genes, GSK3B, AKT1, ARRB2, 
GRIA2 and PPARGC1a. 
 To determine the association of these genetic variants with the type and frequency 
of side effects experienced. 
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Chapter 4. Materials and Methods       
4.1. Cohort selection 
The “Genetics of BPD” project was first approved at the University of Cape Town (UCT) in 
1996 (HREC REF 182/96). Currently, the cohort consists of 883 individuals from 185 families. 
Other projects linked to this initiative, which have already received ethical approval, include 
Presentation and Risk Factors in the Psychobiology of Psychosis and Neuroimaging: The 
Effects of Mindfulness Training in Bipolar Disorder. Ethics approval for this study was 
provided by the Human Research Ethics Committee of UCT (Appendix A: HREC REF: 
431/2012). 
The patients in the cohort are diagnosed using the Structured Clinical Interview for DSM 
Disorders (SCID), which includes information on the response phenotype to all current and 
past treatments. All samples and patient information are collected according to the 
Declaration of Helsinki (World Medical Association, 2008). The patients are routinely 
followed up to update SCID data.  
For the present study, patients on the Division of Human Genetics database with a diagnosis 
of BPD type I, that are known to have been treated with lithium, were retrospectively 
contacted. A side-effect questionnaire (Appendix C) similar to that used by Ghose (1977) was 
applied to determine their side-effect profile. A total of twenty side effects were assessed 
and rating was carried out according to a three-point rating scale: 0 = none, 1 = mild, 2 = 
moderate, 3 = severe. The questionnaire further addressed questions regarding lithium 
dose, time on lithium treatment, adherence to medication, as well as the number and type 
of other psychotropics prescribed to the patient, while on lithium treatment. Lastly patients 
were also asked whether they were ever advised to discontinue lithium treatment by their 
doctor and why.  All questionnaires were conducted telephonically by a registered 
psychiatric nurse within the Division of Human Genetics at UCT. 
Further patient recruitment was conducted at Valkenberg Psychiatric Hospital, Cape Town. 
Patients with a diagnosis of BPD type I (as diagnosed by a registered psychiatrist) and a 
history of treatment with lithium were approached for inclusion in the study. The side-effect 
questionnaire was conducted by either a project researcher or a psychiatric nurse. 
Interviews were conducted in either English or Afrikaans, except for one Xhosa patient for 
whom a translator was used.  
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Informed consent for DNA analysis and storage (Appendix B), as well as access to 
confidential medical records, was obtained from all patients, after which DNA was isolated 
from whole blood for further analysis. When a blood sample could not be obtained, a saliva 
sample was taken using the Oragene·DNA (OG-500) kit (DNA Genotek Inc., Canada) and DNA 
was isolated for further analysis. DNA samples are coded anonymously and stored in the 
molecular genetics laboratory of the Division of Human Genetics at UCT.  
4.2. DNA isolation 
Genomic DNA was isolated from peripheral blood lymphocytes according to the salting-out 
method by Gustafson and colleagues, a detailed protocol of which is provided in Appendix D 
(Gustafson et al., 1987). Following cell lysis and protein precipitation, ethanol precipitation 
of the DNA was performed. Thereafter, the DNA was rehydrated and stored.  
The DNA isolation protocols were completed by a research assistant from the Division of 
Human Genetics. Each DNA sample was assigned a laboratory reference code to ensure 
confidentiality, and patient and family information were recorded on the database. One 
DNA sample is routinely archived at -80°C for long term storage and another at -20°C for 
short term storage. The latter was used for this study, unless that was depleted, in which 
case the other sample was retrieved from long term storage.  
4.3. Concentration and integrity of isolated DNA 
The quality of each of the DNA samples was determined by analysing the concentration and 
purity of the stock samples using the NanoDrop 1000 spectrophotometer (NanoDrop 
Technologies, USA).   
Aliquots of the DNA stock samples were diluted with distilled water (dH2O) to working 
concentrations of 100 ng/µl that were stored at 4°C for the duration of the research project. 
The DNA integrity was determined by electrophoresis of 100ng of diluted DNA combined 
with 5 µl loading buffer (Fermentas Life Sciences, Burlington, Canada). The DNA was 
electrophoresed at 160 V for approximately 20 minutes (min) through a 1% agarose gel 
(Appendix G). Each agarose gel contained 30ng of ethidium bromide (EtBr) (Sigma, England), 
a DNA intercalating agent, to enable visualisation. The DNA was visualised under UV light on 
the UVIPro UVIGold transilluminator (UVItec Limited, UK).  
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High molecular weight DNA appears as a bright solid band closest to the loading well, at the 
top of the agarose gel. DNA fragments of lower molecular weight, in which double-stranded 
breaks have occurred, migrate further than fragments of higher molecular weight. DNA 
which appears as a smear on the gel indicates a degraded sample. 
4.4. Candidate gene and SNP selection 
Candidate genes were selected based on thorough literature searches and biological 
databases queries. Genes were considered candidates if they were reported to be up- or 
down-regulated by lithium treatment, and if they had evidence of biological function in 
tissues involved in lithium-induced side-effects. SNPs in candidate genes were selected 
based on known functional properties, as published in the literature. SNPs were excluded if 
they had a minor allele frequency below 0.05. The genetic variants investigated in this study 
as well as the genotyping method used are indicated in Table 4.1.  
 Table 4.1: List of genes, SNPs and respective genotyping method 
  
Gene Chromosomal Location NCBI RefSNP Identifier Genotyping Method 
GSK3B 3q13 rs334558 SNaPshot PCR 
rs6438552 SNaPshot PCR 
rs3755557 RFLP 
AKT1 14q32 rs1130233 SNaPshot PCR 
rs10138227 TaqMan® 
ARRB2 17p13 rs34230287 SNaPshot PCR 
rs1045280 SNaPshot PCR 
GRIA2 4q32 rs4302506 TaqMan® 
PPARGC1A 4p15 rs8192678 TaqMan® 
rs2279525 TaqMan® 
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4.5. Polymerase Chain Reaction (PCR) 
4.5.1. External Primer design 
The sequences containing the SNP of interest in the candidate genes were amplified using 
Polymerase Chain Reaction (PCR).  External primers, complementary to regions flanking the 
sequence of interest, were designed for PCR amplification. The sequences of each of the 
candidate genes (GSK3B, AKT1, ARRB2, GRIA2 and PPARGC1A) were obtained from NCBI 
(http://www.ncbi.nlm.nih.gov) and Ensembl (http://www.ensembl.org/index.html) 
databases. Gene sequences were then annotated using the ANNOTV9 annotation program 
(Rebello, 2006, Division of Human Genetics, UCT, Personal communication), which utilises 
Perl scripting language (Wall, 1994). The genes are annotated to specify the location of 
exons, start/stop codons, coding sequence and SNPs. 
Each sequence, including approximately 400 base pairs (bp), on either side of the SNP locus 
was submitted in FASTA format to the Primer3 primer selection program 
(http://frodo.wi.mit.edu/primer3/) (Rozen and Skaletsky, 1999). The conditions for primer 
selection were:  primer length between 18 and 23 bp, the melting temperature of the 
primers between 50° and 65°C, GC content between 45% and 55%, a maximum difference in 
melting temperature of 3°C between the primer pair and an amplicon size larger than 100 
bp.  
 The primer pairs obtained from Primer3 were further assessed using the OligoCalculator 
program (http://www.pitt.edu/~rsup/OligoCalc.html) and the Integrated DNA Technologies 
(IDT) OligoAnalyzer version 3.1 web-based tool (http://eu.idtdna.com/analyzer/applications/ 
oligoanalyzer/default.aspx). Using OligoCalculator the length, melting temperature (Tm), 
percentage GC content and molecular weight (in Daltons, g/M) were determined.  IDT 
OligoAnalyzer was used to analyse each primer pair for self-complementarity (hairpin 
formation), homodimer formation (the ability of the primer to self-dimerise) and 
heterodimer formation (dimer formation between the forward and reverse primers). 
The primers were then submitted to the NCBI PrimerBLAST program 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi). The Basic Local Alignment 
Search Tool (BLAST) compares nucleotide or protein sequences to sequence databases and 
determines the statistical significance of similarity between aligned sequences. PrimerBLAST 
is therefore used to determine whether the primer pair is complementary to regions of the 
human genome other than the region of interest.  
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The primers were synthesised by the Department of Molecular and Cell Biology at UCT, using 
the Oligo 1000M DNA Synthesiser v4.20. All stock primer solutions were diluted in dH2O to 
working concentrations of 20 micromolar (µM) and stored at 4°C. External primers for the 
PCR amplification reaction of rs334558, was previously designed (Dalvie, unpublished data, 
2011) and synthesised by the Department of Molecular and Cell Biology at UCT.  The primer 
sequences used to amplify the candidate SNPs are shown in Table 4.2. The table also 
includes the primer length, the size of the DNA fragment expected to result from PCR 
amplification and the optimal annealing temperature (Ta) determined through a 
temperature gradient experiment. 
4.5.2. PCR optimisation 
Prior to amplification of the selected SNPs, each PCR was optimised for annealing 
temperature, cycling conditions and concentration of reagents. A temperature gradient 
experiment, in which the Ta is varied over 12 reactions, was performed to determine the 
optimal annealing temperature (Ta). An example of the result of a temperature gradient 
experiment is shown in Appendix E.  
The PCR reaction (Appendix H) included 100 ng DNA template, 10 picomoles (pmol) of each 
primer (forward and reverse), 200 µM of each deoxyribonucleotide triphosphate (dNTP) 
(Bioline, UK), 0.1 unit (U) GoTaq DNA Polymerase (Promega, USA), 1x Colorless GoTaq 
Reaction Buffer (Promega, USA) and dH2O to make up the final reaction volume of 25 µl. 
Based on the Ta for the primer pairs and the amplicon size, the amplification of rs34230287 
and rs1130233 could be run in one multiplex PCR reaction. A negative (no template) control, 
in which the DNA template is substituted with distilled water, was included in every PCR 
experiment, which allows one to control for contamination of reagents.  
The standard cycling conditions for a PCR was 94⁰C for 3 min, and then repeated 30 cycles 
with 94⁰C for 30 s, the optimal Ta for each primer set (Table 4.2) for 30 s and 72⁰C for 30 s, 
followed by an extension step at 72⁰C for 10 min. PCR reactions were performed on the 
MultiGene™ Gradient Thermal Cycler (Labnet International, Inc., USA). Once completed, PCR 
reactions were stored at 4°C until required for downstream processes. To determine 
whether amplification had occurred, PCR products were electrophoresed at 160 V for 
approximately 40 min through a 1% agarose gel. The first lane of the gel was loaded with 
100bp molecular weight marker (MWM) or 1kb MWM (Fermentas Life Sciences, Burlington, 
Canada) to estimate the size of DNA fragments (Appendix F). The PCR products were 
visualised under UV light on the UVIPro UVIGold transilluminator (UVItec Limited, UK). 
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Table 4.2: External primer sequences for amplification of candidate SNP regions using PCR 
Gene SNP Primer Direction Primer Length Primer Sequence (5’→3’) Ta (°C) Amplicon Size (bp) 
GSK3B  rs334558 Forward 22 CGATTCCCAGACGCCTGTTACG 59 302 
  Reverse 18 TCAGGAAGTGTCCGCGCT   
 rs6438552 Forward 21 CTTTTGGTGCCTTCTTAGGTG 59 286 
  Reverse 20 CGAAACATTGGGTTCTCCTC   
 rs3755557 Forward 23 GTCCTTCATCAGTGTTTCAAAGC 59 250 
  Reverse 20 CCAGCGTCCATTGTTCTACC   
AKT1 rs1130233 Forward 21 ACTTGTTCCTGCTGAGTTAGG 62 419 
  Reverse 22 AGTCTGTGATCTTAATGTGCCC   
 rs10138227 Forward 22 TCTGAACCTCTCTTTGTCTCCA 60 388 
  Reverse 20 CAGCCCCTTTGACTTCTTTG   
ARRB2 rs34230287 Forward 23 GTGAATAGCATAACATAGGCACG 62 494 
  Reverse 21 CAACCCCTTGAAACCGATTGG   
 rs1045280 Forward 20 CAGTGACCAGGTATCTCCCA 59 571 
  Reverse 22 TGAAATCCAGCCCTTTGTGAAG   
GRIA2  rs4302506 Forward 21 GCACATCAACAAACCTAGCAG 60 313 
  Reverse 18 TGCCCACCACTACACCTG   
PPARGC1A rs8192678 Forward 20 CAGGGGCAGATTTGTTCTTC 59 410 
  Reverse 20 GATTTGGGTGGTGACACAGA   
 rs2279525 Forward 20 CTTTTTGCCCTGGATTGTTG 59 549 
  Reverse 20 CCCTCTCTGCTGCTTTGAAT   
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4.6. SNaPshot™ PCR 
SNaPshot™ PCR is a SNP genotyping method based on basic PCR amplification, the basic 
principle of which is demonstrated in Figure 4.1. The method requires the use of SNaPshot™ 
multiplex ready reaction mix (Applied Biosystems, CA, USA), which contains reaction buffer, 
fluorescently-labelled dideoxynucleotide triphosphates (ddNTPs), and AmpliTaq polymerase. 
Internal primers were designed to bind directly 5’ or 3’ of the SNPs of interest in ARRB2 
(rs34230287, rs1045280), GSK3B (rs3755557, rs6438552) and AKT1 (rs1130233). An internal 
primer, for rs334558 in GSK3B, was previously designed (Dalvie, unpublished data, 2011). 
The internal primer anneals to its complementary regions in PCR products of the regions of 
interest. It is then extended through the incorporation of a differentially-labelled ddNTP, 
complementary to the SNP of interest, the reaction of which is catalysed by Taq polymerase 
(ABI Prism SNaPshot™ Multiplex Kit Protocol, Applied Biosystems). Since ddNTPs lack a 3’-
hydroxyl group, their incorporation into the sequence results in sequence termination. The 
SNaPshot reaction is resolved through capillary electrophoresis on an ABI genetic analyser 
and the alleles of every SNP are represented as differently coloured peaks. The ddNTPs are 
labelled as follows: ddATP – dR6G (green), ddCTP – dTAMRATM (black), ddGTP – dR110 
(blue) and ddTTP – dROXTM (red). 
4.6.1. SNaPshot PCR Internal Primer Design 
Internal primers, that bind directly 3’ or directly 5’ to the SNP of interest, were designed 
using the same criteria as those for external PCR primers (section 4.5.1). One primer (either 
forward or reverse) was designed for every SNaPshot PCR reaction. In order to multiplex the 
SNaPshot reaction, the primers had to differ in length to prevent overlap in the SNaPshot 
products. Random, non-complementary tails were added to generate primers of different 
lengths. A local BLAST search, using the sequence alignment program, BioEdit Sequence 
Alignment Editor 7.0.0 (Hall, 1999), was performed to ensure that the primers would not 
hybridise to each other. The primer sequences and their resultant coloured peaks are 
indicated in Table 4.3. 
Internal primers were synthesised by the Department of Molecular and Cell Biology at UCT, 
using the Oligo 1000M DNA Synthesiser v4.20. Primers were diluted in dH2O to working 
concentrations of 20 µM and stored at 4°C. Working solutions of 20 µM was made from 100 
µM stock solution through the addition of dH2O. 
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Figure 4.1: Illustration of the SNaPshot PCR principle. Internal primers are extended 
through the incorporation of fluorescently-labelled dideoxynucleotide triphosphates 
(ddNTPs) directly at the SNP of interest. Following capillary electrophoresis, the genotype of 
the particular SNP is visible as coloured peaks. In this figure the SNaPshot PCR genotyping of 
a TG heterozygote sample is demonstrated. 
4.6.2. FastAP™ and ExoI Clean-up of PCR Products 
Prior to SNaPshot PCR genotyping, excess dNTPs and unincorporated primers had to be 
removed to prevent interference with the SNaPshot genotyping reaction (ABI PRISM® 
SNaPshot™ Multiplex Kit Protocol, Applied Biosystems). FastAP™ (Fermentas Life Sciences, 
Burlington, Canada), is a thermo-sensitive alkaline phosphatase which catalyses the release 
of 5'- and 3'- phosphate groups from DNA. Exonuclease I (ExoI) degrades single-stranded 
DNA in a 3’ to 5’-prime direction, thereby releasing deoxyribonucleoside 5'-monophosphates 
in a stepwise manner, while leaving 5'-terminal dinucleotides intact. This promotes the 
degradation of excess single-stranded primers (Lee et al., 2002). 
The FastAP™ and ExoI purification process was carried out on a GeneAmp® PCR System 9700 
thermal cycler (Applied Biosystems, CA, USA). Thermal cycling was performed at 37°C for 60 
minutes, followed by a 15 minutes at 75°C. The FastAP™and ExoI reaction contained: 5 μl 
PCR product,  1 U  FastAP™ (Fermentas Life Sciences, Burlington, Canada), 2 U ExoI 
(Fermentas Life Sciences, Burlington, Canada) and the volume was made up to a total of 20 
μl using dH2O. 
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Table 4.3: Internal primer sequences for genotyping of SNPs using SNaPshot PCR 
Gene SNP Primer 
Direction 
Expected 
alleles 
Sequence Primer 
length 
Peak Colours 
AKT1 rs1130233 Reverse C/T GTCCTCGGAGAACACACG 18 Black/Red 
ARRB2 rs34230287 Reverse A/G *aaaaCGCCCGCCTTCCAGG 19 Green/Blue 
ARRB2 rs1045280 Forward C/T aGTACACCATAACCCCACTGCTCAG 25 Black/Red 
GSK3B rs6438552 Reverse A/G ggcggcAATGTAAACTGTAACTATCTCT 28 Green/Blue 
GSK3B rs334558 
 
Forward T/C 
 
ttagttagttagttagtaTCCTCACACAGAGCAGC 
 
35 Black/Red 
*Lowercase sequences indicate non-complementary tails 
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4.6.3. SNaPshot PCR Conditions 
The SNaPshot PCR reaction was performed on GeneAmp® PCR System 9700 thermal cycler 
(Applied Biosystems, CA, USA). Cycling conditions consisted of three steps (96°C for 10 s, 
50°C for 5 s and 60°C for 30 s) repeated for 25 cycles. A master mix was made up with 
SNaPshot™ Multiplex Ready Reaction Mix (Applied Biosystems, CA, USA), internal primers 
and dH2O (Appendix H). The master mix was aliquoted and 5 µl cleaned-up PCR product was 
added to each well. Multiplex SNaPshot PCR reactions were performed by including primers 
for two or more SNPs. For each SNaPshot reaction, a negative water control was included, to 
ensure that the results obtained were not due to contamination.  
Following the SNaPshot PCR reaction, one unit of FastAP™ was added to the SNaPshot PCR 
products and the samples were loaded into the GeneAmp® PCR System 9700 thermal cycler 
(Applied Biosystems, CA, USA). Thermal cycling was performed at 37°C for 60 min, 
immediately followed by 15 min at 75°C. This was to ensure that all unincorporated ddNTPs 
were removed from the reaction, to prevent the co-migration of the ddNTPs with the 
products of interest and interference with the genotyping results (ABI PRISM® SNaPshot™ 
Multiplex Kit Protocol, Applied Biosystems). 
4.6.4. Capillary Electrophoresis on ABI PRISM 
The purified SNaPshot products were subjected to capillary electrophoresis on an ABI Prism 
3100 Genetic Analyzer (Applied Biosystems, CA, USA). The SNaPshot product (0.8 µL), 
together with 9 µL Hi-Di™ formamide (Applied Biosystems, CA, USA) and 0.2 µL 
GeneScan™120 Liz™ Size Standard (Applied Biosystems, CA, USA) were loaded into a 96-well 
microtitre plate (Axygen Scientific, USA). Hi-Di is a highly deionised formamide that 
denatures the double-stranded DNA and acts as a buffer to stabilise the single strands of 
DNA. The size standard allows sizing based on the mobility of unknown DNA fragments 
relative to fragments of known size in the size standard. Capillary electrophoresis was 
performed on the ABI Prism 3100 Genetic Analyzer (Applied Biosystems, CA, USA). 
Raw data was collected by the ABI Prism 3100 Genetic Analyzer Data Collection software 
(version 1.1) (Applied Biosystems, CA, USA) and GeneMapper® Software (Applied 
Biosystems, CA, USA) was used to analyse the raw data and size the DNA fragments. 
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4.7. Restriction Fragment Length Polymorphism (RFLP) Analysis 
Restriction endonucleases (REs) are bacterial enzymes that cleave the sugar-phosphate 
backbone of DNA at specific recognition sites. REs are used to perform Restriction Fragment 
Length Polymorphism (RFLP) analysis, in order to genotype a sample for the presence of a 
polymorphism or mutation. RFLP analysis can be used for genotyping if the presence of the 
particular polymorphism or mutation creates or destroys a RE recognition site. The number 
of fragments present after RE digestion will, therefore, differ depending on the alleles 
present in the sample.  
The SNP rs3755557 in GSK3B was genotyped using RFLP analysis. Using Webcutter 2.0 
(Heiman, 1997) the RE, Tru1I, with the restriction site 5’ T/TTAA 3’, was identified as an 
appropriate RE for RFLP analysis of this variant. The presence of the rs3755557 T allele 
abolishes a restriction site and digestion of the 250 bp PCR fragment results in two bands 
(165 and 85 bp) compared to the three bands (165, 57 and 28 bp) obtained when the A 
allele is present.  
Prior to RE digestion of the PCR products, the digest reaction was optimised in terms of 
incubation time and concentration of reagents. The RE digest reaction was made up to a 
total volume of 20 µl. A standard reaction contained 10 µl PCR product, 1x Buffer R 
(Fermentas Life Sciences, Burlington, Canada), 2 Units Tru1I (Fermentas Life Sciences, 
Burlington, Canada) and was made up to the final volume with dH2O. 
The RE reaction was incubated for two hours at the optimum temperature of 65°C on a 
heating block, allowing for complete RE digestion of the PCR products. The digest products 
were electrophoresed at 120 V for approximately 50 min through a 4% agarose gel and 
visualised under UV light.  An undigested PCR product was electrophoresed alongside the 
digested products for comparison, as well as a HyperLadder™ 50bp (Bioline, UK) for 
fragment size estimation (Appendix F). 
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4.8. TaqMan® SNP Genotyping Assay 
The TaqMan® SNP Genotyping Assay (Applied Biosystems, CA, USA), also known as the “5’-
nuclease allelic discrimination assay’’, was used to genotype SNPs in AKT1 (rs10138227), 
GRIA2 (rs4302506) and PPARGC1a (rs8192678, rs2279525). This method uses two allele-
specific TaqMan® minor groove binder (MGB) probes and a PCR primer pair to detect the 
SNP of interest in one thermal cycling reaction. Each allele-specific MGB probe is labelled 
with either 2'-chloro-7'-phenyl-1,4-dichloro-6-carboxyfluorescein (VIC) or C-
carboxyfluorescein (FAM) fluorescent reporter dye and has a fluorescence quencher 
attached to it.  
During PCR amplification, the 5’-nuclease activity of Taq DNA polymerase cleaves the 
reporter dye (FAM or VIC) from a MGB probe that is completely hybridised to the DNA 
strand. Once it is separated from the quencher, the reporter dye fluoresces (Figure 4.2). 
When a single point mismatch is present between the probe and target DNA, as in the case 
of a SNP, the hybridisation of the probe to the DNA is less stable, thereby reducing the 
efficacy of the probe cleavage and quenching of the fluorescent reporter dye (Shen et al., 
2009). When the levels of both fluorescent dyes are equal it indicates heterozygosity at a 
SNP, and where there is an increase in the levels of either FAM or VIC dye fluorescence, it 
indicates homozygosity for the FAM- or VIC-specific alleles. 
 
Figure 4.2: Taqman SNP genotyping reaction of a CC homozygote. a) When the MGB probe completely 
hybridises to the DNA strand, the reporter dye is cleaved from the MGB probe, the quencher (Q) is 
released and the reporter dye (FAM) fluoresces. b) When the MGB probe is not completely 
complementary to the DNA strand, the quencher remains attached to the reporter dye and it does not 
fluoresce. 
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4.8.1. TaqMan® SNP genotyping protocol 
Pre-designed, validated TaqMan® SNP Genotyping Assays were ordered from Applied 
Biosystems, CA, USA. Each of the 40x SNP Genotyping Assays  contain sequence-specific 
forward and reverse primers to amplify the region of interest, and two TaqMan® MGB 
probes, one labelled with VIC® dye to detect Allele 1 and the other with FAM™ dye to detect 
the Allele 2 sequence (Applied Biosystems, 2006). The assays are optimised and designed to 
work with a TaqMan® Universal PCR Master Mix (Applied Biosystems, CA, USA) at the same 
thermal cycling conditions.  
The SNP genotyping assays were diluted to a 20x working stock with 1X TE buffer and 
aliquots were made for routine use to minimize freeze-thaw cycles. In a total reaction 
volume of 10 µl, 20 ng of genomic DNA were mixed with 5 µl TaqMan® Universal PCR Master 
Mix (Applied Biosystems, CA, USA), 0.50 µL of 20x TaqMan SNP Genotyping Assay and dH2O. 
The TaqMan SNP genotyping reactions were aliquoted into wells of a Hard-Shell® PCR plate 
(Bio-Rad Laboratories, Inc., USA) and sealed with Microseal® “B” Adhesive Film (Bio-Rad 
Laboratories, Inc., USA). The cycle sequencing reaction was performed on a Bio-Rad CFX96 
(Bio-Rad Laboratories, Inc., USA) using the recommended conditions: 95°C for 10 min, 
followed by 40 cycles of 92°C for 15 s and 60°C for 1 min.   
Individual samples were assigned to a specific genotype by plotting the end-point relative 
fluorescence units (RFU) of the reporter dyes in each sample well on a Cartesian plot (also 
known as a scatter or cluster plot). A clustering algorithm in the Bio-Rad CFX96™ data 
analysis software (Bio-Rad Laboratories, Inc., USA) assigns individual sample data to a 
particular genotype cluster.  
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4.9. Genotype Validation 
Cycle sequencing is a DNA sequencing technique based on traditional Sanger sequencing, in 
which chain terminating inhibitors are used (Sanger et al., 1977). Cycle sequencing is similar 
to a PCR, with the exception that fluorescently-labelled ddNTPs are incorporated in the 
reaction mix. The ddNTPs lack a 3’-hydroxyl group, therefore their incorporation into the 
sequence by DNA polymerase results in sequence termination. Each ddNTP is labelled with a 
differently coloured fluorescent marker to enable detection. Cycle sequencing was used to 
verify the genotyping results of SNaPshot PCR, RFLP and TaqMan SNP genotyping reactions. 
A subset of samples was selected for sequencing based on genotyping results. One sample 
of all three possible genotypes (homozygous and heterozygous) was selected for each of the 
SNPS. PCR amplification was performed on the samples as previously described (section 4.5). 
PCR products were cleaned-up with FastAP™ and ExoI as described in section 4.6.2. Cycle 
sequencing was performed using the BigDye® Terminator (version 3.1) cycle sequencing kit 
(Applied Biosystems, CA, USA). The terminator mix contained the ddNTPs, as well as the 
thermo-stable DNA polymerase. The sequencing reaction included 1.5 μl PCR product, 0.5 
µM of primer, 0.5 X terminator mix, and 1 X sequencing buffer. Sequencing reactions were 
made up to 20 μl with dH2O. 
All cycle sequencing reactions were performed on a GeneAmp® PCR System 9700 thermal 
cycler (Applied Biosystems, CA, USA). The cycling conditions consisted of an initial 
denaturation step at 95°C for 5 min, 30 cycles consisting of a denaturation step at 96°C for 
10s, an annealing step at 50°C for 15 s and an extension step at 60°C for 4 min. Following 
cycle sequencing, an ethanol precipitation was performed (Appendix H) to remove any 
unincorporated ddNTPs which could interfere with base-calling. Following ethanol 
precipitation, the samples were re-suspended in 10 µl dH2O, and capillary electrophoresis 
performed on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, CA, USA). The results 
were analysed using BioEdit Sequence Alignment Editor Version 7.0.0 (Ibis Biosciences, USA) 
(Hall, 1999).  
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4.10. Statistical Analysis 
Statistical analysis was performed using Microsoft Excel 2010 (Microsoft Corporation, 
Redmond, WA, USA) to calculate Hardy-Weinberg Equilibrium (HWE), while linkage 
disequilibrium analysis was performed using SHEsis (Shi and He, 2005).  The statistical 
environment R version 2.15 (http://www.R-project.org) was used to create a Spearman 
correlation matrix of the relationship between side effects. All genotype-phenotype 
correlations and other analyses were performed using SPSS version 21 (SPSS IBM, New York, 
USA). Normality testing was performed using the Shapiro-Wilk normality test. A p-value 
<0.05 was considered statistically significant for all tests. No correction for multiple testing 
was performed as this was an exploratory pilot study. The reported side effects were 
grouped as absent (zero side effect reported) or present (mild, moderate or severe side 
effect reported). The total side effect frequency was calculated by summing the total 
number of “present” side effects in a patient. 
The relationship between demographics (sex and ethnicity) and lithium dose, lithium level 
and total side effect frequency was assessed by the Mann-Whitney Test. The relationship 
between total side effect frequency and lithium dose and lithium level were assessed by 
Spearman correlation. Variables significantly associated with total side effect frequency 
were further investigated for association with individual side effects using Pearson’s Chi-
squared test.  
To assess the effect of other psychotropics on the side effect profile of patients, individuals 
on lithium monotherapy were compared to individuals using lithium in combination with 
other psychotropics. An Independent T-test was used to compare the total number of side 
effects experienced between these two groups. The contribution of the different types of 
other psychotropics (anticonvulsants, antidepressants and antipsychotics) on the presence 
or absence of individual side effects was determined through Chi-squared analysis.  
The association of genetic polymorphisms in AKT1, ARRB2, GSK3B, GRIA2 and PPARGC1A on 
the presence of each of the twenty side effects was investigated using a Chi-squared test. 
Significant results from the Chi-squared analysis were further assessed using logistic 
regression to determine whether the genetic associations remained significant after 
potential covariates (sex, age, ethnicity and the use of other psychotropics) were taken into 
account.  
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Backwards stepwise regression was applied using the likelihood-ratio test to eliminate 
variables from the model in an iterative process. The model is tested after the elimination of 
each variable to determine whether the model adequately fits the data. The analysis is 
complete when no more variables can be eliminated from the model. An Odds Ratio (OR) 
was calculated as a measure of risk. The corresponding 95% confidence interval (95% CI) was 
also calculated. 
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Chapter 5.  Results 
5.1. Cohort description and DNA extraction 
The study cohort consisted of 105 individuals with a diagnosis of BPD I and a history of 
treatment with lithium. Of the cohort, 68 (64.8%) were female and 37 (35.2%) male; 38 
(36.2%) were of Mixed Ancestry and 60 (57.1%) were Caucasian (represented in Figure 5.1). 
The average age (±SD) of the study participants at the time of interview was approximately 
46 (±11.68) years and ranged from 26 to 77 years. Seventy-two of the patients in the cohort 
were recruited previously and contacted telephonically to collect further information about 
side effects that were experienced while they were on lithium treatment. The remaining 
patients (n=33) were recruited from Valkenberg Psychiatric Hospital (Observatory, Cape 
Town). 
A prerequisite of admission into the study was the availability of biological material from the 
research subjects. Generally, this was in the form of EDTA blood, which was processed to 
DNA using the salting-out method. DNA samples were quantified by means of 
spectrophotometry (NanoDrop Technologies, USA), and integrity determined by 
electrophoresis through a 1% agarose gel an example of which is given in Appendix D.  
n=60 
n=38 
n=4 
n=2 n=1 
Figure 5.1 The distribution of the patient cohort (n=105) in terms of ethnicity and sex 
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Figure 5.2: Chromatogram of SNaPshot results for Group A multiplex reaction. The X-axis 
represents the size or base position of the alleles and the Y-axis represents the relative fluorescent 
units. The coloured panes from left to right indicate the following alleles: blue plane – rs34230287 G 
allele, yellow pane – rs1130233 C allele, red pane – SNP 4 T allele, green pane – rs34230287 A allele, 
blue pane – rs6438552 G allele, Green pane – rs6438552 A allele. Orange peaks represent 
Genescan-120 Liz size standard. Genotypes in a): rs34230287 – heterozygote AG, rs1130233 – 
heterozygote CT, rs6438552 – heterozygote AG. Genotypes in b): rs34230287 – homozygous GG, 
rs1130233 – homozygous CC, rs6438552 – homozygous GG. 
a) 
b) 
5.2. SNP genotyping results 
5.2.1. SNaPshot™ PCR reaction 
Two multiplex SNaPshot PCR genotyping reactions were performed in order to save time 
and reagents. The first multiplex reaction (Group A) included rs34230287, rs1130233 and 
rs6438552 and the second (Group B) included rs334558 and rs1045280.  The PCR products 
for the two SNaPshot reactions were multiplexed from the FastAP™ and ExoI clean-up stage.    
The genotypes for five SNPs were therefore incorporated in two SNaPshot multiplex 
reactions. Chromatograms of Group A and B are given in Figures 5.2 and 5.3. In the 
chromatogram, homozygous genotypes are visible as a single, large peak. Heterozygous 
genotypes are indicated by two overlapping or adjacent peaks of a different colour.  
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5.2.2. Restriction Fragment Length Polymorphism Analysis 
Following PCR amplification, the SNP rs3755557 was genotyped by RE digestion. An example 
of the results obtained is shown in Figure 5.4. The 250bp PCR product was digested by Tru1I 
into 165bp, 57bp and 28bp fragments when an A allele was present, while the T allele 
resulted in digested fragments of 165bp and 85bp.  
CC 
 
Figure 5.3: Chromatogram of SNaPshot results for Group B multiplex reaction. The X-axis represents 
the size or base position of the alleles and the Y-axis represents the relative fluorescent units. The 
coloured panes from left to right indicate the following alleles: yellow plane – rs1045280 C allele, red 
pane – rs1045280 T allele, yellow pane – rs334558 C allele, red pane – rs334558 T allele. Orange 
peaks represent Genescan-120 Liz size standard. Genotypes in this reaction: rs1045280 – 
heterozygote CT, rs334558 – heterozygote CT. 
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Figure 5.4: Representative RFLP SNP genotyping results for rs3755557 following Tru1I digestion 
showing AA, AT and TT genotypes. MWM indicates the 50 bp molecular weight marker: 
HyperLadder™ 50bp (Bioline, UK). An undigested PCR product was run with the products of every 
RE digest. All digest products were electrophoresed through 4% agarose gels stained with EtBr at 
120 V for 60 min and visualised under UV light. 
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5.2.3. TaqMan® SNP Genotyping Reaction 
Rs10138227 in AKT1, rs4302506 in GRIA2, and rs8192678 and rs2279525 in PPARGC1A were 
genotyped using pre-designed TaqMan® SNP genotyping assays. The results were analysed 
using Bio-Rad CFX96™ system software (Bio-Rad Laboratories, Inc., USA). The end-point RFU 
levels of the FAM and VIC fluorophores in every sample well were plotted on a Cartesian or 
allelic discrimination plot and RFU values were normalised relative to the negative controls, 
to assign a sample to a specific genotype (Figure 5.5). 
FAM-labelled homozygous alleles are located in the top left quadrant, VIC-labelled 
homozygous alleles in the bottom right quadrant and heterozygotes are located in the upper 
right quadrant.  
 
Figure 5.5: An allelic discrimination plot of rs8192678 in PPARGC1A following TaqMan® 
SNP Genotyping. The major allele (G allele) was detected by VIC-labelled probes and the 
minor allele (A allele) by FAM-labelled probes. The genotyping results are presented as 
allelic discrimination plots with the normalised relative fluorescent units (NRFU) of VIC on 
the X-axis and the NRFU of FAM on the Y-axis. Homozygotes for the VIC-labelled allele are 
located in the bottom right quadrant, homozygotes for the FAM-labelled allele in the upper 
left quadrant and heterozygotes in the top right quadrant.    
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5.2.4. Genotype Validation 
The genotyping for all SNP results were validated by sequencing the PCR products of one 
sample from every genotype as determined by SNaPshot, TaqMan® or RFLP analysis. A total 
of 30 samples were therefore sequenced. Figure 5.6 represents a portion of the sequencing 
results of rs2279525 in PPARGC1A. The sample shown in figure 5.6 was homozygous for the 
G allele.  The SNP is visible as blue peak (C allele) at position 95 (as indicated by the arrow), 
as the sequencing reaction was performed with the reverse primer. Figure 5.7 represents a 
heterozygous sample (C/T) for rs1045280 in ARRB2. 
 
 
 
 
 
5.3. Genotype and allele frequencies 
The genotype frequencies of the SNPs in GSK3B, AKT1, ARRB2, GRIA2 and PPARGC1A are 
indicated in Table 5.1. HWE was calculated for the total cohort and the genotype 
frequencies of one SNP (rs334558) deviated from HWE (p=0.049). When analysing the HWE 
of the Caucasian and Mixed Ancestry populations alone, however, no SNPs deviated from 
HWE. A chi-squared test was conducted and genotype frequencies did not differ significantly 
between the Caucasian and Mixed Ancestry population groups at the p=0.05 level, except 
for the SNP rs334558 in GSK3B. The other population groups were not included in this 
calculation as there were only four Black African patients, two Indian and one Asian patient 
in the cohort.  
Figure 5.6: Sequencing results for rs2279525 in PPARGC1A. This sample is a homozygous for 
the G allele, seen here as a C allele, that is visible as a blue peak at position 95 (indicated with 
the arrow). 
Figure 5.7: Sequencing results for rs1045280 in ARRB2. This sample is heterozygous (C/T) and 
the alleles are visible as a red and blue peak at position 111 (indicated with the arrow). 
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Table 5.1: Overall and population-specific genotype frequencies of genetic polymorphisms in GSK3B, AKT1, ARRB2, GRIA2 and PPARGC1A 
Genotype All patients 
Number 
(percentage) 
Hardy Weinberg 
Equilibrium 
(p-value) 
Population group Population 
comparison 
Hardy Weinberg Equilibrium 
(p-value) 
Caucasian Mixed 
Ancestry 
p-value Caucasian Mixed 
Ancestry 
rs334558 in GSK3B 102  59 36    
CC 32 (31.37) 0.049 13 (22.0) 16 (44.4) 0.047 0.20 0.17 
CT 41 (40.20)  24 (40.7) 13 (36.1)    
TT 29 (28.43)*  22 (37.3) 7 (19.4)    
rs6438552 in GSK3B 103  59 37    
CC 30 (29.13) 0.970 14 (23.7) 13 (35.1) 0.475 0.70 0.73 
CT 51 (49.51)  31 (52.5) 17 (45.9)    
TT 22 (21.36)  14 (23.7) 7 (18.9)    
rs3755557 in GSK3B 102  59 36    
AA 71 (69.61) 0.258 43 (72.9) 24 (66.7) 0.542 0.81 0.23 
AT 30 (29.41)  15 (25.4) 12 (33.3)    
TT 1 (0.98)  1 (1.7) 0 (0.0)    
rs1130233 in AKT1 102  58 37    
GG 55 (53.92) 0.649 26 (44.8) 25 (67.6) 0.081 0.59 0.87 
GA 41 (40.20)  27 (46.6) 11 (29.7)    
AA 6 (5.88)  5 (8.6) 1 (2.7)    
rs10138227 in AKT1 105  60 38    
GG 78 (74.29) 0.998 41 (68.3) 31 (81.6) 0.275 0.54 0.32 
GA 25 (23.81)  18 (30.0) 6 (15.8)    
AA 2 (1.90)  1 (1.7) 1 (2.6)    
rs34230287 in ARRB2 101  59 35    
CC 76 (75.25) 0.377 40 (67.8) 30 (85.7) 0.105 0.52 0.11 
CT 22 (21.78)  18 (30.0) 4 (11.4)    
TT 3 (2.97)  1 (1.7) 1 (2.9)    
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rs1045280 in ARRB2 102  59 36    
 TT 56 (54.90) 0.664 35 (59.3) 19 (52.8) 0.164 0.51 0.20 
 TC 38 (37.25)  22 (37.3) 12 (33.3)    
 CC 8 (7.84)  2 (3.4) 5 (13.9)    
rs4302506 in GRIA2 105  60 38    
 CC 45 (42.86) 0.893 28 (46.7) 15 (39.5) 0.106 0.39 0.26 
 CT 47 (44.76)  28 (46.7) 15 (39.5)    
 TT 13 (12.38)  4 (6.7) 8 (21.1)    
rs8192678 in PPARGC1A 104  58 38    
GG  61 (58.65) 0.595 29 (50.0) 26 (68.4) 0.203 0.99 0.44 
 GA 36 (34.62)  24 (41.4) 10 (26.3)    
 AA 7 (6.73)  5 (8.6) 2 (5.3)    
rs2279525 in PPARGC1A 104  59 38    
 AA 52 (50.0) 0.059 28 (47.5) 19 (50.0) 0.385 0.90 0.07 
 AG 37 (35.58)  25 (42.4) 12 (31.6)    
 GG 15 (14.42)  6 (10.2) 7 (18.4)    
*Values in brackets indicate percentages
67 
 
5.4. Linkage Disequilibrium Testing 
Linkage disequilibrium (LD) analysis was performed for the three SNPs in the GSK3B gene, 
the two SNPs in AKT1, the two SNPs in ARRB2 and the two SNPs in PPARGC1A. LD was 
calculated for the Caucasian and Mixed Ancestry population groups. Pairwise linkage 
disequilibrium coefficient (D´) and correlation coefficient (r2) values are reported in Table 
5.2. The r2 should be similar to D’ values, as both are measures of linkage disequilibrium; 
however r2 value are dependent on allele frequencies and these values were much lower 
than D’ values. This discrepancy may be due to the small sample size and differences in 
minor allele frequency between SNPs. The r2 is preferred by the HapMap project and were 
used in this study. According to this measure, no tight LD was observed between any of the 
SNPs and no haplotypes could be inferred. 
If the D’ value is taken in to account, however, the D’ value of 1.000 indicated that the three 
SNPs in GSK3B (rs334558, rs3755557 and rs6438552) are in complete LD in Caucasians. In 
the Mixed Ancestry population, the D’ (0.831) between rs334558 and rs6438552 indicate 
tight, but not complete LD. A D’ value of 0.998 indicated that rs10138227 and rs1130233 in 
AKT1 were in tight LD in the Mixed Ancestry population, but LD was weaker in Caucasians 
(0.724). 
Table 5.2: Linkage disequilibrium analysis of GSK3B, AKT1, ARRB2 and PPARGC1a 
Gene SNP Pair Caucasian Mixed Ancestry 
D’ R2 D’ R2 
GSK3B rs3755557-rs334558    1.000 0.231 1.000 0.129 
 rs3755557-rs6438552 1.000 0.160 1.000 0.129 
 rs334558-rs6438552 1.000 0.691 0.831 0.690 
AKT1 rs10138227-rs1130233 0.724 0.045 0.998 0.026 
ARRB2 rs34230287-rs1045280 0.710 0.346 0.012 0.000 
PPARGC1a rs2279525-rs8192678 0.832 0.128 0.415 0.022 
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5.5. Side effect frequencies 
Data was collected regarding twenty common side effects that patients may experience 
while on lithium treatment. Patients were asked to rate the severity of a specific side effect 
on three-point rating scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe 
The median number of side effects reported was six (variance 13.013). A histogram of the 
distribution of side effect frequency is indicated in Figure 5.8. Three patients reported 
experiencing zero side effects while on lithium. The maximum number of side effects 
reported was nineteen. This patient was an outlier that was removed in further analyses as 
the individual reported experiencing nineteen of the twenty potential side effects, although 
(other than weight gain and thyroid problems), these were all reported to be mild. 
The frequency and severity of the different side effects is shown in Figure 5.9. The most 
common reported side effect was polydipsia (75.2%), followed by a dry mouth (71.6%) and 
polyuria (60.4%). Over 40% of patients reported polydipsia to be severe. 54.4% of patients 
reported to have gained weight while on lithium treatment and 17.3% reported this as 
severe weight gain. Similarly, 54.4% of patients reported experiencing tremors. Tremor was 
mild in the majority (27.9%) of patients. The least common side effect was a congested (or 
stuffy) nose (7.7%).  
 
 
 
 
 
 
 
 
 
 
Figure 5.8: Distribution of the number of side effects 
reported by patients. The median number of side effects 
reported was 6 (Variance=13.013). 
Median=6.00 
Variance=13.013 
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A skin problem was reported by 24% of patients. Twelve patients had acne, seven had 
extremely dry skin and three suffered from psoriasis. One patient suffered from Hidradenitis 
Suppurativa (skin disease that most commonly affects areas bearing apocrine sweat glands 
or sebaceous glands), two complained of consistent rash and one was diagnosed with 
dermatitis.  
Of the cohort, three patients had to discontinue lithium treatment due to kidney problems, 
although the severity of kidney damage was not assessed. Lithium toxicity occurred in five 
patients, although it is unclear whether this was due to intentional or accidental lithium 
overdose. Severe weight gain was a further reason given for discontinuing lithium 
treatment, as well as feelings of being “numb” or “like a zombie”. 
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Figure 5.9: Incidence and severity of reported lithium-induced side effects. 
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5.5.1. Correlations between side effects 
A  Spearman's correlation was performed to assess the relationship between different side 
effects and to determine whether any side effects cluster together. There were no complete 
correlations between side effects, with the strongest correlation being between polyuria and 
polydipsia at 0.563 and between polydipsia and dry mouth at 0.535. Weak correlations were 
also observed between the gastrointestinal side effects. There was a correlation of 0.349 
between indigestion and constipation and a correlation of 0.323 between indigestion and 
nausea. A correlation matrix is shown in figure 5.10 and a table with all correlation values 
are given in Appendix I.  
Figure 5.10: A Spearman’s correlation matrix of investigated side effects. The strongest 
correlation is between polydipsia and polyuria at r=0.56. 
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5.5.2. Demographic and clinical variables 
There was no significant correlation between lithium dose and the total side effect 
frequency in patients (r2=0.038, p=0.728).The median prescribed daily lithium dose was 800 
mg, with a significant difference between males and females (p=0.030). The median dose for 
men was 1000 mg and for females this was 750 mg lithium per day (Figure 5.11). There was 
no significant difference in the lithium dose between patients of Caucasian or Mixed 
Ancestry origin (p=0.706).  
 
Figure 5.11: Distribution of lithium dose in males and females. The median dose for males 
is 1000mg per day and for females it is 750mg per day. 
Information on lithium levels in blood was only available for 17 patients. There was no 
correlation between lithium levels and the number of side effects experienced (r2=0.346, 
p=0.147). Patients were requested to report their treatment adherence, but all patients 
reported a 75-100% adherence rate and this information was therefore not taken into 
account in further analysis. 
It was further investigated whether total side effect frequency differs in terms of 
demographics (sex and ethnicity) using a Mann-Whitney Test. A summary of the descriptive 
data is given in table 5.3. There was a significant difference in the total number of side 
effects experienced between males and females, p=0.041. The median number of side 
effects in males (5.00) was lower than in females (7.00).  
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To determine which specific side effects contributed to the sex-difference in total side 
effects, side effects were individually investigated, using a Chi-squared analysis. There was a 
significant difference in the frequency of three side effects between sexes, namely tremor 
(p=0.035), constipation (p=0.001) and stuffy nose (p=0.048). Tremor and constipation were 
both more prevalent in females and the only individuals to report experiencing a congested 
nose were female.  
Table 5.3: Descriptive statistics of the side effect frequency in patients stratified in terms 
of sex and ethnicity 
  N Mean Standard 
Deviation 
Median Variance Minimum Maximum 
Sex Male 37 5.57 3.524 5.00 12.419 0 13 
 Female 68 6.97 3.266 7.00 10.666 0 16 
Ethnicity Caucasian 60 5.90 3.373 6.00 11.380 0 13 
 Mixed 
Ancestry 
38 7.13 3.481 7.50 12.117 1 16 
The median number of side effects in Caucasian patients were 6.00 (Variance=11.380) and 
7.50 (Variance =12.117) in Mixed Ancestry patients. The total side effect frequency did not 
differ significantly between these two groups, p=0.081, but since the p-value was near 0.05 
the side effects were investigated individually. There was a significant difference in the 
frequency of polydipsia (p=0.046), constipation (p=0.013), indigestion (p=0.001), metallic 
taste (p=0.041) and blurred vision (p=0.021), which were all more frequently reported by 
patients of Mixed Ancestry. Figure 5.12 demonstrates the proportional difference in side 
effect frequency between Caucasians and patients of Mixed Ancestry. Patients from other 
ethnic groups were excluded from this analysis due to small sample size. 
Figure 5.12: Proportional side effect frequency in Caucasian and Mixed Ancestry patients  
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5.5.3. The effect of other psychotropics on side effects 
The influence of other psychotropics on the side effects experienced while on lithium was 
investigated, as several of the side effects of lithium are similar to those caused by other 
psychotropics. Data on other drugs used was not available for eleven patients as they could 
not remember their treatment regimen at the time of lithium use.  Of the remaining patient 
cohort, 23.4% were treated with lithium alone.  Nearly 77% of the cohort was therefore 
treated with between one and four other psychotropics. Of these patients 40.4% were also 
taking one or two anticonvulsants, 24.5% typical antipsychotics, 34.0% atypical 
antipsychotics and 26.6% were taking one or two antidepressants.      
The group on lithium monotherapy was compared to the group of patients taking additional 
psychotropics. The frequency of side effects was normally distributed for the groups on 
lithium monotherapy and those taking other additional psychotropics, as assessed by 
Shapiro-Wilk's test (p > 0.05). A boxplot of this data is given in Figure 5.13.  
Descriptive statistics of the side effect frequency in patients on lithium monotherapy and 
those using other additional psychotropics is given in Table 5.4. The mean number of side 
effects in the lithium monotherapy group was 6.86 (±3.705) and 6.10 (±3.188) in the group 
taking other psychotropics. There was no statistically significant difference in the side effects 
frequency in the two groups of patients, p=0.349.  
The individual types of psychotropics were further investigated for association with the 
presence or absence of specific side effects. Nausea was negatively associated with the use 
of anticonvulsants (p=0.032) and memory and concentration problems were positively 
associated with the use of antipsychotics (p=0.042). Nausea appeared to be lower in patients 
taking anticonvulsants (6.7%) than in patients not being treated with anticonvulsants 
(22.5%).  
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Table 5.4: Descriptive statistics of the side effect frequency in patients on lithium 
monotherapy and patients using other additional psychotropics 
 N   Mean Std. 
Deviation 
95% Confidence Interval for 
Mean 
Minimum Maximum 
Lower Bound Upper Bound 
Lithium 
Monotherapy 
21  6.86 3.705 5.17 8.54 1 12 
Other 
Psychotropics 
72 6.10 3.118 5.36 6.83 0 13 
 
 
 
Figure 5.13: A boxplot of the side effects frequency in patients on lithium monotherapy 
versus patients taking other additional psychotropics.  
  
75 
 
5.6. Genotype-phenotype associations 
A Kruskal-Wallis test was performed to determine if there were differences in the total 
number of side effects experienced between the different genotype groups of every SNP. 
There was no significant difference between the total number of side effects experienced 
and any of the SNP genotypes. 
Next, a Chi-squared test for association was conducted to determine whether there is an 
association between genotypes of the ten candidate SNPs and the presence or absence of a 
particular side effect while on lithium treatment. Due to the small sample size, a genotypic 
genetic model could not be tested, as the majority of tests would have had one or more 
expected values smaller than five. Chi-squared tests for association were therefore 
conducted by grouping heterozygotes and minor allele homozygotes together. In cases 
where one or more expected frequencies were less than five, the Fisher’s exact test was 
used. The results of the Chi-squared tests for association in the whole cohort are indicated in 
Table 5.5.  
At the p<0.05 level, there was an overall significant association between nausea and 
rs10138227 in AKT1 (p=0.045), with nausea more prevalent in homozygotes of the major 
allele (G). Polydipsia was associated with rs2279525 in PPARGC1A (p=0.034) and more major 
allele (A allele) homozygotes experienced polydipsia. 
Memory and concentration problems were associated with rs6438552 in GSK3B (p=0.028), 
with the proportion of individuals experiencing memory and concentration problems higher 
in major C allele homozygotes.  Weight gain was overall associated with rs1130233 (p=0.022) 
in AKT1, with a larger proportion of patients with the GA or AA genotype gaining weight.  
Body ache (p=0.030), as well as skin problems (p=0.005) were associated with rs8192678 in 
PPARGC1A. Skin problems were more likely to occur in individuals homozygous for the major 
G allele, while body ache was more prevalent in carriers of the minor A allele. Lastly, 
rs4302506 in GRIA2 was associated with indigestion (p=0.012), and indigestion was more 
frequently reported by carriers of the minor T allele. Bar plots of these associations is given 
in Figure 5.14. 
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Table 5.5: Chi-squared test for association of SNPs on presence or absence of side effects in complete cohort. Italicized results indicate that the Fisher’s 
exact test was used. 
Side Effect 
GSK3B AKT1 ARRB2 GRIA2 PPARGC1A 
rs334558 rs6438552 rs3755557 rs1130233 rs10138227 rs34230287 rs1045280 rs4302506 rs8192678 rs2279525 
Nausea 0.732 0.488 0.732 0.072 0.045 0.054 0.232 0.143 0.650 0.147 
Diarrhoea 0.623 0.578 0.099 0.168 0.552 0.111 0.335 0.124 0.817 0.053 
Tremor 0.796 0.772 0.185 0.904 0.450 0.959 0.174 0.541 0.211 0.551 
Polydipsia 0.590 0.794 0.620 0.988 0.766 0.864 0.945 0.949 0.715 0.034 
Polyuria 0.482 0.862 0.599 0.218 0.304 0.940 0.251 0.793 0.680 0.801 
Concentration problems 0.089 0.028 0.055 0.401 0.297 0.269 0.081 0.159 0.784 0.551 
Body ache 1.000 0.763 0.771 0.090 0.343 0.518 0.051 0.161 0.030 0.425 
Drowsiness 0.813 0.956 0.568 0.266 0.881 0.899 0.639 0.222 0.227 0.780 
Constipation 0.303 0.181 0.507 0.866 0.366 0.589 0.606 0.304 0.892 0.335 
Indigestion 0.726 0.560 0.201 0.627 1.000 1.000 0.750 0.012 0.828 0.131 
Dry Mouth 0.405 0.128 0.093 0.712 0.736 0.845 0.214 0.428 0.763 0.795 
Headache 0.726 1.000 0.900 0.561 0.549 0.645 0.054 0.849 1.000 0.757 
Stuffy nose 1.000 1.000 1.000 1.000 0.425 0.675 0.290 1.000 0.202 1.000 
Weight gain 0.863 0.872 0.511 0.022 0.331 0.753 0.059 0.831 0.353 0.233 
Metallic taste 0.612 0.678 0.834 0.089 0.577 0.096 0.196 0.659 0.929 0.297 
Poor appetite 0.825 0.560 0.483 0.627 1.000 0.759 0.750 0.072 0.589 0.199 
Dizziness or Giddiness 0.615 0.804 0.360 0.394 0.874 0.671 0.491 0.801 0.977 0.668 
Blurred vision 0.574 0.799 0.667 0.507 0.446 1.000 0.294 0.261 0.637 0.875 
Thyroid Problems 0.763 0.753 0.754 0.162 0.509 0.295 0.553 0.946 0.287 1.000 
Skin Problems 0.052 0.094 0.066 0.528 0.797 0.589 0.070 0.705 0.005 0.526 
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Figure 5.14: Bar plots of SNPs with significant association (p<0.05) with presence of a side effect 
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5.6.1. Logistic regression modelling 
Significant results were further assessed using backward stepwise logistic regression to 
determine whether the genetic associations remained significant after potential covariates 
(sex, age, ethnicity and the use of other psychotropics) were taken into account. In the case 
of genetic variables the major allele was used as the reference group to determine ORs. The 
result of the logistic regression analysis is given in Table 5.6. Variables that remained in the 
final step of the backward stepwise regression, with the respective p-values, OR and 95% CI 
for the ORs are given in the table.  
The genetic variants that were further investigated were all included in the final step of the 
logistic regression models for the respective side effects. Only three genetic variants were 
statistically significant predictors on their own, rs6438552 as a predictor for memory and 
concentration problems (p=0.034), rs1130233 for weight gain (p=0.034) and rs8192678 for 
skin problems (p=0.033). 
ORs indicated that carriers of the minor allele of rs6438552 were less likely to experience 
memory and concentration problems than individuals homozygous for the major allele 
(OR=0.309, 95% CI=0.104-0.916). The use of antipsychotics was also predictive of memory 
and concentration problems and individuals treated with antipsychotics in addition to 
lithium were 2.64 times (95% CI=1.037-6.722, p=0.042) more likely to experience these 
cognitive problems. 
Carriers of the minor allele of rs1130233 in AKT1 were 2.727 times more likely to experience 
weight gain than individuals homozygous for the major allele (95% CI=1.079-6887). 
Antidepressants also remained as a covariate in the final step of the model, however, it was 
not a significant predictor for weight gain on its own (p=0.065). Individuals homozygous for 
the major allele of rs8192678 in PPARGC1A were 4.27 more likely to experience skin 
problems, with carriers of the minor allele being protected against skin problems (OR=0.234, 
95% CI=0.062-0.891).  
The other genetic variants were not significant predictors on their own. Anticonvulsants and 
the variant rs10138227 were predictors of nausea. Of the two predictor variants, only 
anticonvulsants were statistically significant and not rs10138227. Individuals treated with 
anticonvulsants were 3.37 times (OR=0.297, 95% CI 0.095-0.922, p=0.034) less likely to 
experience nausea than patients not taking anticonvulsants.  
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Both sex and ethnicity remained, together with rs4302506 in GRIA2, as covariates in the final 
step of the logistic regression model for indigestion. Only ethnicity was a significant 
predictor of indigestion on its own, with individuals of Mixed Ancestry being 7.163 times 
more likely to experience indigestion than Caucasians (95% CI=1.748-29.351). In the logistic 
regression model of polydipsia, age was a significant predictor (p=0.027, OR=0.939, 95% 
CI=0.888-0.993). Although not a statistically significant predictor, only rs8192678 remained 
as a covariate in the logistic regression model of body ache. OR indicated that carriers of the 
minor allele were 3.333 times more likely to experience body ache than major allele 
homozygotes (95% CI=0.916-12.128). 
Table 5.6: Result of backward stepwise logistic regression analysis  
Side effect Covariates p-value Odds* 
Ratio 
95% CI** 
Upper  Lower 
Memory and Concentration  Antipsychotics 0.042 2.641 1.037 6.722 
rs6438552 0.034 0.309 0.104 0.916 
Weight gain Antidepressants 0.065 0.379 0.135 1.062 
rs1130233 0.034 2.727 1.079 6.887 
Nausea Anticonvulsants 0.036 0.297 0.095 0.922 
 rs10138227 0.083 0.301 0.077 1.171 
Indigestion Ethnicity 0.006 7.163 1.748 29.351 
 Sex 0.117 0.268 0.052 1.394 
 rs4302506 0.081 3.614 0.855 15.273 
Body ache rs8192678 0.068 3.333 0.916 12.128 
Skin problems rs8192678 0.033 0.234 0.062 0.891 
Polydipsia Age 0.027 0.939 0.888 0.993 
rs2279525 0.077 0.351 0.110 1.120 
*Major allele of SNP is reference group for each Odds Ratio  
**95% CI – 95% confidence interval for the Odds Ratio of each variable 
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Chapter 6. Discussion 
BPD is a severe, debilitating psychiatric illness that affects millions of individuals worldwide. 
There is no single cure or guaranteed treatment of BPD and it cannot be disputed that 
improved treatments are needed. Evidence-based drug development for BPD and other 
psychiatric disorders are limited as the aetiology of these diseases is not fully understood 
and the exact cause of the disease can therefore not be treated.  
Several drugs are available to manage the symptoms of BPD, but due to disease 
heterogeneity and pharmacogenetic factors, treatment response varies significantly from 
patient to patient. The mood stabiliser, lithium, is the first-line treatment for BPD and many 
patients have an excellent response to lithium, tolerate it well, and are stabilized for years, while 
others do not. Response to lithium appears to have a strong genetic component and 
polymorphisms in several genes (amongst others PLCG1, BDNF, FYN, 5’-HTTLPR, INPP1 and 
GSK3B) have been associated with lithium response in some but not all studies. As there are 
no good predictors of response, determining the most effective treatment for a patient is 
conducted through a trial-and-error basis that can last months, prolonging patient suffering. 
One of the main factors hindering the effectiveness of lithium in clinical practice is treatment 
non-adherence. In BPD patients, the rates of non-adherence range from 10 to 60% (Pompili 
et al., 2009). Patients often discontinue lithium treatment due to ADRs, such as weight gain 
and cognitive problems (Johnson et al., 2007), even if their mood symptoms are effectively 
managed with lithium.  If the occurrence of side effects could be predicted prior to 
treatment initiation, alternative treatment could be considered or side effects could be 
managed before they occur. 
In spite of association of ADRs with lithium dose and lithium serum levels, there are no 
accurate predictors of these side effects in lithium-treated patients. In the present pilot 
study, it was investigated whether certain genetic markers could be used to predict whether 
a patient would experience side effects while on lithium treatment. To the investigator’s 
knowledge, no previous studies of the influence of genetic factors on lithium-induced ADRs 
have been reported, except for a recent study that reported an association of a SNP in 
GSK3B with renal concentrating ability (Rybakowski et al., 2013b). 
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A pilot study can be defined as an “investigation designed to test the feasibility of methods 
and procedures for later use on a large scale or to search for possible effects and 
associations that may be worth following up in a subsequent larger study” (Everitt, 2006). As 
this was an exploratory pilot study, the cohort size was small and the power to detect 
significant association was therefore low.  
Correction for multiple testing was not conducted as interesting results for further research 
(as found in this study) would not have been detected. Multiple testing refers to the 
repeated use of a statistical test when multiple genes and interactions are considered. When 
considering a specific null hypothesis, the risk of type I errors (false positive results) 
increases with multiple testing. In exploratory studies, such as this study, however, there is 
no pre-specified key hypothesis that is tested and correction for multiple testing is not 
strictly required (Bender and Lange, 2001). Any significant results from this study are merely 
exploratory and to confirm these results the corresponding specific hypotheses have to be 
tested in further confirmatory studies. 
6.1. Allele and genotype frequencies of SNPs 
The majority of individuals in this study were part of two population groups, Caucasians and 
Mixed Ancestry. The genotype frequencies of SNPs did not differ significantly between these 
two groups, except for one SNP, rs334558, in GSK3B. The Mixed Ancestry (or Coloured) 
population of South Africa is a highly admixed, but discrete ethnic group that arose from 
indigenous Khoisan, tribal Bantu-speaking populations, European settlers, and slaves’ 
descendants from south Asia (Quintana-Murci et al., 2010).  
The allele frequencies in the Caucasian and Mixed Ancestry populations in the current study 
were compared to allele frequencies of Caucasians (CEU) included in the HapMap study 
(Table 6.1). There was a significant difference in allele frequencies of three SNPs (rs6438552, 
rs34230287 and rs8192678) between Caucasians and the HapMap CEU population. 
Interestingly, the allele frequencies of only one SNP, rs6438552 in GSK3B, differed 
significantly between the Mixed Ancestry group and the HapMap CEU population.  
SNPs in GSK3B have previously been associated with BPD and the difference in allele 
frequency may therefore be due to only cases, and no healthy individuals, being included in 
this study. In a large meta-analysis the GSK3B variant, rs334558, was nominally associated 
with BPD (Seifuddin et al., 2012), however, no association was found with BPD I in our 
cohort in a previous study (Dalvie, unpublished data, 2011).  
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Even though these differences in allele frequencies should be further investigated in larger 
control populations, it highlights the importance of the study of population genetic diversity, 
as large differences may exist between population groups that may be assumed to be 
ethnically similar. This is important to take into account especially for association studies 
where population stratification can lead to false positive results. 
According to the r2 measure, no tight LD was observed between any of the SNPs and no 
haplotypes could be inferred. If the D’ value is taken in to account, however, the D’ value of 
1.000 indicated that the three SNPs in GSK3B (rs334558, rs3755557 and rs6438552) are in 
complete LD in Caucasians and in tight LD in the Mixed Ancestry population. This is 
consistent with previous studies that found rs334558 and rs6438552 to be in LD (Kwok et al., 
2005). The South African Caucasian population, especially the Afrikaner subset, is also 
known to be relatively homogenous and a high level of LD is observed (Hall et al., 2002).  
Table 6.1: Comparison of allele frequencies in the study cohort with Caucasian HapMap 
(CEU) populations 
Gene 
 
SNP Minor 
Allele 
Study Cohort 
 
HapMap 
CEU 
(n=113) 
Comparison (p-
value) 
Caucasian 
(n=60) 
Mixed 
Ancestry 
(n=38) 
Caucasian Mixed 
Ancestry 
 
GSK3B rs334558 T 0.38 0.58 N/A N/A N/A 
 rs6438552 T 0.42 0.5 0.67 0.0001 0.009 
 rs3755557 T 0.17 0.14 0.18 0.783 0.404 
AKT1 rs1130233 A 0.18 0.32 N/A N/A N/A 
 rs10138227 A 0.18 0.17 0.14 0.309 0.533 
ARRB2 rs34230287 T 0.09 0.17 0.21 0.007 0.504 
 rs1045280 C 0.31 0.22 0.32 0.924 0.119 
GRIA2 rs4302506 T 0.41 0.30 0.36 0.361 0.376 
PPARGC1A rs8192678 A 0.18 0.29 0.35 0.001 0.337 
 rs2279525 G 0.34 0.31 0.28 0.247 0.537 
N/A: not available 
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6.2. Side effects 
This study investigated the prevalence and severity of twenty of the most common side 
effects associated with lithium treatment. Further, the role of demographics, dose, serum 
lithium levels and the use of other psychotropics on side effect prevalence and severity, was 
investigated.  
Almost all (97.2%) of the cohort reported experiencing at least one side effect, with only 
three patients (2.8%) reporting  no observable side effects while on lithium treatment. 
Nephrogenic symptoms were the most commonly experienced side effects in our cohort. 
Polydipsia was reported by 75% of the patients, a dry mouth by 71% and polyuria by 60%. 
This is consistent with other studies that found approximately 70% of their cohort to 
experience increased thirst and urination (Vestergaard et al., 1980). Although not measured 
in this study, it has been found that almost all patients have an irreversibly reduced 
maximum urinary concentration capacity after 15 years on lithium treatment (Bendz et al., 
1996; Bendz et al., 2009). A meta-analysis by McKnight and colleagues reported glomerular 
filtration rates to be reduced by – 6.22 ml/min and the urinary concentrating ability by 15% 
of normal maximum (McKnight et al., 2012). Three patients in this cohort had to discontinue 
lithium treatment due to kidney problems and at least one of these patients is known to 
have permanent renal damage. In a recent meta-analysis the absolute risk of developing 
renal failure was reported to be only 0.5% (McKnight et al., 2012). Due to the seriousness of 
renal failure, however, serum creatinine levels should be routinely tested and lithium-
treatment discontinued before any permanent renal damage can occur. 
Gastrointestinal side effects, such as nausea, vomiting, and diarrhoea are common 
complaints in lithium-treated patients and previous studies report that up to 50% of patients 
may experience one or more of these complaints (Bowden et al., 2000). In this study, 31% of 
patients reported experiencing nausea, 25% constipation, 18% diarrhoea, and 17% 
complained of indigestion. These side effects are often transitory, but may be the first sign 
of lithium toxicity and therefore needs to be monitored (Macritchie and Young, 2004). The 
frequency of constipation was significantly higher in females than in males. Constipation is 
more prevalent in females than in males in the general population, which may explain the 
difference in prevalence in this study, which is also consistent with other studies (McCrea et 
al., 2009). 
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Tremor was experienced by 54% of patients when lithium treatment was first started. 
Individual studies on tremor show variability of 4% to 65%, with the average frequency of 
tremor estimated to be about 27% of patients treated with lithium (Gelenberg and 
Jefferson, 1995). In this study tremor was experienced significantly more by females (62.7%) 
than in males (40.5%). This differs from previous studies, which found the frequency of 
tremor to be equal in males and females (Vestergaard et al., 1988)  or more common in 
males (54%) than in females (33%) (Vestergaard et al., 1980). 
Endocrine side effects of lithium, such as thyroid dysfunction can have dire consequences 
when not properly managed. In this study, the frequency of thyroid problems was 14%, 
although the severity of the specific thyroid problems was not measured.  The prevalence of 
hypothyroidism in the general population ranges from 2-3% (Flynn et al., 2004). In lithium-
treated patients overt and subclinical hypothyroidism has been reported to be 8-19% and 
23%, respectively (Kleiner et al., 1999). In the Chinese population, lithium-treated patients 
also experienced a higher rate of hypothyroidism (28-32%) than BPD patients not treated 
with lithium (6.3-10.8%) (Zhang et al., 2006). A recent meta-analysis, reported 
hypothyroidism to be more common in lithium-treated patients than controls, and TSH was 
increased by 4.00 iU/mL (95% CI 3·90–4·10, p<0·0001) on average (McKnight et al., 2012). 
Nearly half (46%) of the present cohort reported experiencing memory and concentration 
problems, i.e. cognitive problems, while on lithium treatment. Poorer cognitive performance 
is a common impairment in BPD patients and studies have shown BPD patients to have 
impaired functioning across a range of cognitive domains, independent of treatment 
(Martinez-Aran et al., 2005). Lithium therapy has been associated with minor negative 
effects on cognition (Wingo et al., 2009). 
Weight gain is a frequent and significant problem in patients with BPD, with or without the 
influence of medication.  In this study, weight gain was reported by 55% of patients, 
compared to 25-50% of patients in previous studies (Keck Jr and McElroy, 2002; Goodwin 
and Jamison, 2007). A prospective study conducted over seven years, reported weight gain 
to occur during the first two years of lithium treatment, after which weight stabilised 
(Vestergaard et al., 1988). Weight gain may be explained by fluid retention, increased 
appetite, lithium-related subclinical hypothyroidism or a combination of these and other 
biological or genetic factors (Torrent et al., 2008).  
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Dermatological side effects of lithium treatment can be very distressing for patients and 
negatively affect treatment adherence. In controlled trials, 3.4–45% of patients treated with 
lithium developed dermatological side effects, with acne and psoriasis the most common 
(Yeung and Chan, 2004). A quarter of this cohort reported experiencing a dermatological 
side effect, with the most common complaints being acne and unusually dry skin. 
Headaches and body aches were experienced by 17% and 15% of the cohort, respectively. 
This is consistent with other studies, in which headaches were reported by 13.2-23.9% of 
lithium-treated patients (El-Mallakh et al., 2012). In the same study the combined 
percentage of extremity pain, musculoskeletal stiffness and back pain was 11.9-18.1% (El-
Mallakh et al., 2012). 
The experience of a metallic taste (dysgeusia) was reported by 34% of patients. This may be 
due to a reduction in salivary flow, which concentrates electrolytes in the saliva, resulting in 
a metallic taste. Other side effects that were reported in more than 20% of patients were 
drowsiness (31%), blurred vision (28%) and dizziness (21%). 
Lithium dosage did not have a significant effect on the total prevalence of side effects. This 
may be due to the fact that serum lithium levels were routinely tested in these patients and 
dose was therefore stabilised within the therapeutic serum range. In previous studies, 
lithium serum level was associated with prevalence and severity of reported side effects 
(Wilting et al., 2009). In this study, there was no correlation between lithium serum levels 
and side effect prevalence. Due to incomplete patient folders and a lack of access to the 
records of some patients, the levels of only seventeen patients were known to the 
researcher, and accurate conclusions cannot be drawn.  
Patient sex was associated with the total prevalence of side effects, with specifically tremor, 
constipation and a congested nose being significantly more prevalent in females than males. 
Patient ethnicity was also associated with the frequency of some side effects, with 
polydipsia, constipation, indigestion, metallic taste and blurred vision reported more 
frequently by patients of Mixed Ancestry. The difference in these side effects may be 
influenced by genetic differences between these population groups, but may also be 
influenced by cultural, socio-economic and other population-specific environmental factors.  
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The number or type of concomitant medications did not significantly affect the prevalence 
of side effects. This is contradictory to other studies that found that side effects increased 
with number of drugs (Serretti et al., 2013). Specific treatment type also did not have an 
association with individual side effects, except for two side effects.  
Memory and concentration problems were significantly associated with treatment with 
antipsychotics (p=0.042), and nausea with the use of anticonvulsants (p=0.036). Memory 
and concentration problems have previously been reported to be associated with 
antipsychotics in the large STEP-BD study (Serretti et al., 2013).  
6.3. Genotype-Phenotype associations 
The main aim of this study was to determine whether variants in five selected candidate 
genes are risk factors for the development of side effects while treated with lithium. 
Associations were found between genetic variants in four of the five candidate genes and 
several side effects, including weight gain, skin and cognitive problems.   
6.3.1. Associations with AKT1 
Two side effects of lithium were associated with SNPs in AKT1. Weight gain was associated 
with rs1130233 in AKT1, and nausea was associated with rs10138227 in AKT1. The 
association of nausea, however, did not remain significant when the association of nausea 
with anticonvulsant use was taken into account.  
AKT1 (or Protein Kinase B) is a serine/threonine-protein kinase involved in the regulation of 
several growth factors. AKT1 regulates glucose transporter 4 (GLUT4), GSK3, and tuberous 
sclerosis complex 2 (TSC2)-mTOR signalling pathways thereby stimulating glucose uptake 
(Welsh et al., 2005), glycogen synthesis (Cross et al., 1995) and protein synthesis (Ruggero 
and Sonenberg, 2005; Memmott and Dennis, 2009). Akt activation in skeletal muscles leads 
to muscle hypertrophy (Rommel et al., 2001) and reduced fat accumulation (Izumiya et al., 
2008). In insulin-resistant tissues of obese mice AKT/mTOR activity is decreased (Shao et al., 
2000) and GSK3B activity increased (Kaidanovich-Beilin and Woodgett, 2011). Akt1 
transgene-induction in obese mice leads to muscle growth, weight loss and the 
improvement of metabolic disorders (Izumiya et al., 2008).   
Lithium treatment leads to increased Akt expression in the striatum, frontal cortex, and 
hippocampus of rodents (Beaulieu et al., 2004) and concurrent increase in GSK3 
phosphorylation and inhibition (Chalecka-Franaszek and Chuang, 1999), which would 
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normally not be associated with weight gain. Weight gain was more frequently reported by 
carriers of the AKT1 rs1130233 minor A allele, in which expression of AKT1 is significantly 
reduced when compared to major allele homozygotes (Tan et al., 2008). These individuals 
may be less susceptible to the effects of lithium on AKT1 expression.  
Higher levels of AKT1 (in patients homozygous for the major allele) may therefore be 
protective against lithium-induced weight gain and modify a patient’s likelihood of gaining 
weight while on lithium treatment. 
6.3.2. Associations with PPARGC1a 
The SNP rs8192678 in PPARGC1a was associated with body ache and skin problems and 
rs2279525 was associated with polydipsia. Skin problems were reported by 24% of subjects, 
and were associated with the G allele in the PPARGC1a SNP rs8192678. PPARGC1a encodes 
for a transcriptional co-activator, PGC-1α, which increases the transcriptional activity of 
several nuclear receptors, including PPAR-α and PPAR-γ. Decreased activity of PPAR-α and 
PPAR-γ and of multiple genes regulated by these nuclear receptors, can be seen in several 
skin conditions, including atopic dermatitis (Plager et al., 2007) and psoriasis (Romanowska 
et al., 2010). PPARs have anti-inflammatory activity in the skin and modulate epidermal 
proliferation (Schmuth et al., 2008).  
The A allele of rs8192678 in PPARGC1a is associated with reduced mRNA expression and 
lower levels of PGC-1α (Ling et al., 2008). The expression of PPARGC1a is inhibited by lithium 
in human neuronal cell lines (Seelan et al., 2008) and to almost undetectable levels in brown 
preadipocytes during brown fat differentiation (Rodr  guez de la Concepci n et al., 2005). The 
inhibition of PPARGC1a by lithium may lead to decreased transcriptional activity of PPAR-α 
and PPAR-γ, and increased risk of inflammatory skin conditions or skin conditions associated 
with increased cell turnover.   
Individuals carrying the A allele of rs8192678 were more likely to experience body ache, 
although in the logistic regression model of body ache, rs8192678 was not a significant 
predictor of this side effect. However, the association seen with Chi-squared analysis may 
also be mediated through PPARs. PPARs play an essential role in inflammation which may 
contribute to joint pain (Jhaveri et al., 2008). In addition, mice lacking PPAR-α have shown 
higher sensitivity to neuropathic pain (Ruiz-Medina et al., 2012) and PPAR-α agonists 
suppress pain behaviour in mice (LoVerme et al., 2006). 
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Although also not significant in the logistic regression model, the association of the 5’UTR 
variant rs2279525 in PPARGC1a with polydipsia is of interest due to the important role of 
this co-activator in the kidneys. PGC-1α is expressed at high levels in the kidneys where it is 
particularly important for its role in oxidative metabolism and mitochondrial biogenesis 
(Bjornholm and Zierath, 2005).  
The repression of PGC-1α expression resulted in downregulation of important mitochondrial 
enzymes and the loss of and morphological changes to mitochondria (Czubryt et al., 2003). 
PGC-1α has been demonstrated to be essential for the maintenance of mitochondrial 
function in podocytes (Yuan et al., 2012). Podocytes are glomerular epithelial cells that are a 
critical component of the glomerular ﬁltration barrier in the kidneys; and have been 
reportedly damaged in some patients with lithium-induced nephrotoxicity (Markowitz et al., 
2000). In addition, PPAR agonists can affect glomerular and tubular cells to modify acute and 
chronic kidney injury (Ruan et al., 2008; Wang et al., 2010). Impairment of PPAR and PGC-1 α 
signalling has been reported in cisplatin-induced acute kidney injury (Portilla et al., 2002). It 
has further been ascertained that PPARs are significantly involved in a mouse model of X-
linked nephrogenic diabetes insipidus (Schliebe et al., 2008). 
6.3.3. Associations with GSK3B 
Cognitive problems were reported by 45% of subjects, and of the GSK3B SNPs investigated, 
rs6438552 C allele homozygotes were 3 times more likely to report these than carriers of the 
T allele. This variant influences GSK3B alternative splicing; the T allele of rs6438552 results in 
greater levels of the GSK3B more active exon9+11 isoform and increased enzyme activity in 
human lymphocytes (Kwok et al., 2005). GSK3B inhibition has positive effects on 
neurogenesis (King et al., 2013) and is protective against inflammation and apoptosis (Song 
et al., 2002; Watcharasit et al., 2002). The rs6438552 T allele is associated with a poor 
response to lithium, measured by recurrence of episodes (Lin, 2012).  
The effect of lithium on cognition in BPD patients has been repeatedly studied, but results 
remain contradictory, in particular because neurocognitive deficits are very common in BPD 
patients regardless of treatment (Balanzá-Martínez et al., 2010; Dias et al., 2012). Several 
studies have concluded that the cognitive abilities of lithium-treated BPD patients does not 
differ from medication-free patients, while others have found lithium to have a mild 
negative effect on attention, verbal learning and memory, and short-term memory (King et 
al., 2013). A meta-analysis on lithium and cognition concluded that lithium only has minor 
negative effects on cognition (Wingo et al., 2009).  
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In conditions with symptoms of cognitive impairments, the administration of GSK3 inhibitors 
has significantly enhanced cognitive abilities. In Alzheimer’s disease (AD), for example, the 
upregulation of GSK3 is thought to be the link between β-amyloid and tau protein, and GSK3 
upregulation has been used to model AD pathologies (Martinez et al., 2011).  
Lithium treatment reduced neuropathology and cognitive deficits in these models through 
inhibition of GSK3 (Rockenstein et al., 2007). Studies of the effect of moderate dosages of 
lithium or other GSK3B inhibitors on cognition in healthy rodents or humans, however, 
indicated mild or no effects (King et al., 2013).  
In BPD patients, the long-term administration of lithium and the less active C allele of the 
GSK3B promoter SNP, rs334558, have both been associated with increases in measures of 
axial diffusivity in several white matter tracts, which reflects the integrity of axons and 
myelin sheaths (Benedetti et al., 2012). The C allele of rs334558 was also associated with 
protective effects against grey matter loss in schizophrenia (Benedetti et al., 2010). Similarly, 
variation in grey matter volume in patients with MDD has been associated with rs6438552 
(Inkster et al., 2009). On the other hand, GSK3 inhibition by lithium elicits NFAT/Fas 
mediated neuronal apoptosis, which may lead to, amongst others lithium-induced motor 
deficits (Gómez-Sintes and Lucas, 2010). In this study, a trend towards association (p=0.089) 
was seen between cognitive problems and rs334558 in GSK3B, but these problems were 
proportionally more common in individuals homozygous for the C allele and the C allele was 
therefore not protective as in previous studies (Benedetti et al., 2010). 
In a recent study on SNPs involved in late-onset AD, the minor T allele of rs6438552 was 
associated with a protective effect against AD, and the CC genotype was twice as common in 
AD patients as in controls (Izzo et al., 2013). The protective effect of the T allele was, 
however, dependent on the Apolipoprotein E (APOE) status of the patients, indicating it to 
be a risk factor for APOE*4-positive carriers (Izzo et al., 2013).  
Similarly, in a study of Parkinson’s disease (PD) the effect of GKS3B polymorphisms were 
dependent on other risk factors. The transcriptionally more active TT haplotype of rs334558 
and rs6438552 increased or decreased the risk for PD depending on the microtubule-
associated protein Tau (MAPT) haplotype (Kwok et al., 2005). This may be owing to the 
differential phosphorylation of Tau by the different splice variants of GSK3B (Soutar et al., 
2010).   
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The inhibition of GSK3B may, therefore, elicit positive or negative effects on cognition 
depending on several other factors. This has also been demonstrated in a rodent model, 
where the overexpression of GSK3B lead to spatial memory impairments (Hernández et al., 
2002), and deficits in object recognition tasks that were reversed when GSK3B levels were 
restored to normal (Engel et al., 2006). Yet, in a GSK3B hypogene model, spatial memory 
was similar to wild type mice, but long-term memory formations were adversely affected 
(Kimura et al., 2008). 
The results of this study may be important to consider in the proposed development of 
drugs that selectively inhibit GSK3B for both the treatment of mood disorders (Li et al., 2011) 
and AD (Mondragón-Rodríguez et al., 2012), as the response of a patient may be altered by 
the patient’s genotype. Functional studies are also needed to further elucidate the 
differential role of splice variants of GSK3B (influenced by rs6438552), which may 
significantly alter the protein function and its interaction with other proteins, such as Tau 
and APOE (Soutar et al., 2010). 
6.3.4. Associations with GRIA2 
Glutamate receptor, ionotropic, AMPA 2 (GRIA2) is one of a family of glutamate receptors 
that are sensitive to AMPA, and function as ligand-activated cation channels. These channels 
are assembled from four related subunits, namely, GRIA1-4.  GRIA2 is essential for the 
channel to be permeable to calcium. GRIA2 is down-regulated by chronic lithium treatment 
in human neuronal cell lines (Seelan et al., 2008) and chronic lithium treatment decreases 
the levels of GluR2 in hippocampal neurons (Du et al., 2008). 
Although it did not remain significant in a logistic regression model, chi-squared analysis 
indicated a variant in GRIA2, rs4302506, to be associated with reported indigestion in 
patients. Indigestion is a common side effect of glutamate supplements, and we hypothesise 
that lithium-induced decrease of glutamate receptors in the gut may contribute to 
indigestion. 
Glutamate is a multi-functional amino acid and in addition to its role as neurotransmitter, it 
plays a critical role in the stomach and intestine. Both ionotropic (e.g. GRIA2) and 
metabotropic glutamate receptors occur in the gut, where the presence of protein digestion 
is signalled in the gastrointestinal tract via glutamate (Burrin and Stoll, 2009). The intra-
gastric glutamate stimulates the limbic system and hypothalamus, as well as gastric 
contractile activity (Sengupta et al., 2004).  
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Although not previously studied (to the author’s knowledge), downregulation of glutamate 
receptors, such as GRIA2, may therefore contribute to indigestion. The variant rs4302506 is 
a synonymous coding variant and is not predicted to be harmful, but may be in LD with a 
functional variant. 
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6.4. Limitations and future directions 
The current study was a pilot and due to the relatively small sample size there was not 
sufficient power to determine true association. In addition, no causal relationship can be 
determined from associations in this study. As side effects were subjectively reported, it is 
difficult to assess the true severity and how common side effects are in patients; and since 
data was collected retrospectively, the accuracy of the patient’s memory also needs to be 
taken into account.  
The majority of the cohort was telephonically contacted and often not on lithium treatment 
at the time of the interview, which may cause a form of recall bias. A possible cofounder 
may also be the two methods through which patients were contacted (telephonically and 
personally within the hospital). Some patients recruited from the hospital have not been on 
lithium treatment for as long a long period of time and their memory of side effects may 
therefore be more accurate (or more severe) than patients who have received treatment for 
a longer period of time.  Data on serum lithium levels were also not always available, and 
since serum lithium levels have previously been associated with the prevalence and severity 
of ADRs, this data is important for future studies. 
Future studies on lithium ADRs should be prospective rather than retrospective, as the 
severity of a side effect can be noted as it occurs, and the duration recorded. Access to 
objective laboratory measures on factors such as urine concentrating capacity and TSH 
levels, accurate records of weight changes, and physician observations on tremor would also 
be advantages of a prospective study. As the number of side effects has been linked to mood 
state in previous studies of side effects in BPD patients (Wilting et al., 2009; Serretti et al., 
2013), mood state at the time of side effect reporting should also be evaluated. 
The findings of this study should further be investigated in larger, better characterised 
cohorts to determine whether results can be replicated. As this was a pilot study, no 
correction for multiple testing was performed, which significantly increases the risk of type I 
errors.  Results may also be significantly influenced by population stratification. Functional 
studies on the investigated variants are also necessary as the statistical significance of a 
genotype with a phenotype does not illustrate the biological mechanism for risk. Therefore, 
the underlying biology needs to be determined through functional analysis of the SNPs.  
The associated SNP rs2279525, in PPARGC1a, is located in the 5’UTR and the SNP rs1130233, 
in AKT1, and rs4302506, in GRIA2, are synonymous SNPs and the impact on gene function is 
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unknown. Instead of affecting protein function or formation directly, the SNPs may affect 
how genes are regulated and expressed, or be in LD with a functional SNP. Understanding 
the function of the SNPs would help to elucidate the mechanism of lithium’s interaction with 
or effect on these genes. 
Future genetic studies on lithium response or lithium-induced ADRs may also consider taking 
a pathway-based approach, as opposed to a candidate gene approach. For a 
pharmacogenetic test to be useful in clinical practice, it must provide more information than 
can be obtained from clinical history. No pharmacogenetic finding on lithium response has 
managed to accomplish this and each genetic polymorphism reported, in this and other 
studies, only accounts for a small portion of the total variance. Evidence suggests that high-
penetrance variants capable of explaining the full genetic variability are rare. It is, therefore, 
likely that (as with BPD) lithium response is polygenic and any single gene may have multiple 
polymorphic alleles. Multiple genes and multiple variants within these genes would 
therefore have to be examined to form the basis of a genetic test. 
One way to approach this problem is to investigate candidate pathways instead of candidate 
genes. GWAS and genome-wide expression studies allow for the discovery of new genes not 
previously discovered, which can be analysed and organised with various bioinformatic tools 
to prioritise the multitude of interactions between genes. Candidate pathway approaches 
make the assumption that a phenotype such as response to lithium (including the 
development of ADRs) may arise from multiple, distinct elements of a common biological 
process. These variants (concentrated within a pathway) may have more robust effects than 
distantly related variants. Through epistasis, these related genes may interact to modify the 
effects of a specific variant. As lithium’s mechanism of therapeutic action (and its off-target 
effects) are known to involve several complex and inter-related processes, a candidate 
pathway approach to its investigation may be more successful than traditional methods. 
A further dimension of drug response that should be investigated is the possible effect of 
gene environment (GxE) interactions. Studies on MDD have indicated that environmental 
factors may explain some of unexplained heterogeneity in treatment response (Keers and 
Uher, 2012). In a study of 383 patients treated with the antidepressant escitalopram, the SS 
genotype of 5-HTTLPR was associated with poor response, but only when the patient 
reported experiencing one or more stressful life events (Keers et al., 2011). As 
environmental factors are known to play a role in the etiology of BPD, these same factors 
could also modulate response to amongst others, lithium treatment. 
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6.5. Conclusion 
The current study showed that interindividual susceptibility to developing side effects on 
lithium treatment may be mediated by genetic factors. Surprisingly, concomitant treatment 
with other psychotropics was not significantly associated with lithium ADRs, except for 
associations between nausea (with anticonvulsants) and memory and concentration 
problems (with antipsychotics). Of particular interest, is the associations found in this study 
between weight gain and an AKT1 variant, cognitive (memory and concentration) problems 
and a GSK3B variant and cutaneous problems and a SNP in PPARGC1a. These side effects can 
negatively contribute to patient adherence and understanding some of the genetic factors 
contributing to interindividual susceptibility may aid in better management of patients with 
BPD. This study further contributes to our understanding of lithium’s mechanism of action. 
This is a pilot study and cannot have an immediate impact on treatment prediction. It, 
however, lays the foundation for future studies, the results of which may be important in 
not only the prediction of response to lithium, but also in the development of new 
pharmacotherapies for BPD through target-based drug discovery.  
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Electronic Resources 
National Centre for Biotechnology Information (NCBI):  
http://www.ncbi.nlm.nih.gov/ 
NCBI PrimerBLAST program: 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi 
OligoAnalyzer (v3.1 2011 Integrated DNA technologies):  
http://eu.idtdna.com/analyzer/applications/ oligoanalyzer/default.aspx 
OligoCalculator: 
http://www.pitt.edu/~rsup/OligoCalc.html 
Ensembl: 
http://www.ensembl.org/index.html 
Primer3 primer selection program: 
http://frodo.wi.mit.edu/primer3/ 
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Appendix C: Side effect Questionnaire 
 
 
 
 
Lithium Side Effect Questionnaire 
Contact details: 
Name:                      Surname:       
Cell number:                     Email address:       
Lithium questions: 
Date you started on lithium treatment?       
How would you rate your compliance to lithium? Do you take your medication:  
75-100% of the time  51-75% of the time  26-50% of the time  Less than 25% of the time  
What was/is the usual daily dose of lithium that you’re on?        
Do you know your current lithium serum level?       
Can you remember whether you are/were on any other medications while taking lithium? If yes, what? 
      
Please score each of the following symptoms in terms of severity according to nil (=0), mild (=1), moderate (=2) 
and severe (=3)  
In first few weeks after starting lithium treatment did you suffer from? 
Nausea                      0  1  2 3  
Diarrhoea            0  1  2 3  
Tremor                    0  1  2 3  
Excessive Thirst           0  1  2 3  
Passing urine too often          0  1  2 3  
While being on lithium treatment did you suffer from?
Memory/concentration problems    0  1  2 3  
Body ache              0  1  2 3  
Drowsiness           0  1  2 3  
Constipation            0  1  2 3  
Indigestion            0  1  2 3  
Dry mouth           0  1  2 3  
Headache           0  1  2 3  
Stuffy nose           0  1  2 3  
Weight gain           0  1  2 3  
Metallic Taste            0  1  2 3  
Poor appetite            0  1  2 3  
Dizziness or giddiness          0  1  2 3  
Blurred vision           0  1  2 3  
Thyroid problems          0  1  2 3  
Skin problems           0  1  2 3   
Specify which skin problems:         
 
Did the doctor advise you to stop lithium treatment? If yes what was the reason? 
      
Any additional comments regarding your treatment with lithium:       
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Appendix D: DNA isolation from blood  
Salting-out method adapted from Gustafson et al. 1988 (Gustafson et al., 1987) 
 
1. Obtain buffy coat by centrifuging the sample at 2 000rpm for 10mins 
2. Remove 500 μl of buffy and plasma  
3. Add 900 μl red blood cell (RBC) lysis solution and incubate at 37⁰C for 1 hour 
4. Centrifuge at 2 500 rpm for 10mins  
5. Remove supernatant and add 1 000 μl RBC lysis solution to pellet 
6. Centrifuge 2 500 rpm/ 10 mins  
7. Decant supernatant and resuspend the pellet in residual RBC lysis solution 
8. Add 300 μl  Cell Lysis Solution, 10 μl of 20% SDS and 2 μl of 20mg/ml Protease K 
9. Vortex well 
10. Incubate overnight or at room temperature until the solution clears (~2hours) 
11. Add 200 μl of saturated 6M NaCl and vortex vigorously 
12. Incubate at 4⁰C for 5 mins 
13. Pellet cellular debris at 2 500 rpm for 15 mins 
14. Remove 500 μl of supernatant and add to a fresh tube containing 900 μl ice-cold 
100% EtOH  
15. Mix by inversion (50X)  and spin at 10 000rpm for 2mins 
16. Decant the solution and add 400 μl ice-cold 70 % EtOH 
17. Resuspend pellet by vortex 
18. Recover DNA by centrifuging at 10 000 rpm for 2 mins 
19. Pour off EtOH and allow to air dry for 2 hours 
20. Resuspend in 100 μl 1X TE for at least 2 days 
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Figure B: Agarose gel electrophoresis of a temperature gradient experiment used for PCR 
optimisation of rs1045280 in ARRB2. MWM indicates a 1kb molecular weight marker: GeneRuler™ 1kb 
DNA Ladder Plus (Fermentas Life Sciences, Burlington, Canada), C indicates a no template control. The 
annealing temperatures are as follows: 1 - 48°C, 2 -  48.7°C, 3 – 49.3°C, 4 – 50.9°C, 5 – 52.7°C, 6 – 
54.4°C, 7 – 55.2°C, 8 – 56.7°C, 9 – 58.1°C, 10 – 59.3°C, 11 – 59.6°C, 12 – 60°C.  PCR products were 
electrophoresed through 1% agarose gels stained with EtBr at 160V for 40 min, and visualised under UV 
light. 
 
DNA quality determination 
DNA integrity was determined by electrophoresis through a 1% agarose gel. Bands, on the 
gel, which appear thick and bright were indicative of non-degraded, good quality DNA. DNA 
fragments of lower molecular weight, in which double-stranded breaks have occurred, 
migrated further than fragments of higher molecular weight. DNA which appeared as a 
smear on the gel indicated that the DNA samples were degraded. An example of a DNA 
integrity gel is given in Figure A. 
 
Appendic E: Temperature gradient experiment for PCR optimisation 
  
Figure A: Agarose gel electrophoresis of DNA isolated from peripheral blood lymphocytes. Low and 
high molecular weight DNA samples are indicated with arrows. A smear on the gel indicates that the 
DNA is slightly degraded, as in lanes 1 and 4. All DNA samples were electrophoresed through 1% agarose 
gels at 160V for 20 min stained with EtBr, and visualised under UV light. 
 
High molecular weight DNA 
Low molecular weight DNA 
1 2 3 4 5 6 7 8 
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Appendix F: Molecular Weight Markers and Size Standards 
GeneRuler™ 100 bp DNA Ladder Plus (Fermentas Life Sciences, Burlington, Canada) 
 
(Adapted from: http://www.thermoscientificbio.com/nucleic-acid-
electrophoresis/generuler-100-bp-plus-dna-ladder-ready-to-use-100-to-3000-bp/) 
GeneRuler™ 1kb DNA Ladder Plus (Fermentas Life Sciences, Burlington, Canada) 
(Adapted from: http://www.thermoscientificbio.com/nucleic-acid-
electrophoresis/generuler-1-kb-dna-ladder-ready-to-use-250-to-10000-bp/) 
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HyperLadder™ 50bp (Bioline, UK) 
 
Adapted from: (http://www.bioline.com/h_prod_detail_ld.asp?itemid=152) 
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Appendix G: Reagents, Buffers and Solutions 
10X Tris-borate-EDTA (TBE) buffer (stock) 
 108 g tris (hydroxymethyl) aminomethane 
 55 g boric acid 
 7.4 g ethylenediaminetetra-acetic acid (EDTA) 
 
Dissolve and make up to a final volume of 1 litre with distilled water. Dilute as required. 
 
1x TBE Buffer (working stock) 
 
1:10 dilution was made with stock TBE buffer using dH2O. 
6x DNA Loading dye (Fermentas Life Sciences, Burlington, Canada) 
 10 mM Tris-HCl (pH 7.6) 
 0.03% bromophenol blue 
 0.03% xylene cyanol FF 
 60% glycerol 
 60 mM EDTA 
Dilute to 1x with distilled water. 
1% Agarose gel  
 1 g SeaKem® LE Agarose (Lonza, USA) 
 100 ml 1x TBE buffer 
 6 µl (5 ng/µl) ethidium bromide (Sigma, England)  
2% Agarose gel 
 2 g SeaKem® LE Agarose (Lonza, USA) 
 100 ml 1x TBE buffer 
 6 µl (5 ng/µl) ethidium bromide (Sigma, England) 
4% Agarose gel 
 4 g SeaKem® LE Agarose (Lonza, USA) 
 100 ml 1x TBE buffer 
 6 µl (5 ng/µl) ethidium bromide (Sigma, England) 
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Appendix H: General Protocols 
Standard PCR reaction mixture 
 
Reagents used in the SNaPshot PCR genotyping reaction 
Reagent Singleplex Multiplex 
Cleaned-up PCR product 1 µl 5 µl 
SNaPshot™ Multiplex Ready Reaction Mix 1 µl 1 µl 
Primers 1 µl 1µl (pooled) 
dH2O 7 µl 3 µl 
Total Volume 10 µl 10 µl 
 
Ethanol Precipitation following cycle sequencing 
1. Transfer cycle sequencing reaction product to a 1.5ml eppendorf tube. 
2. Add 50 µl chilled 100% ethanol and 2 µl chilled sodium acetate 
3. Vortex to mix and hold at -20°C for 2 hours 
4. Centrifuge at 10 000rpm for 10 min and discard the supernatant 
5. Add 30 µl chilled 70% ethanol and vortex to mix 
6. Centrifuge at 10 000rpm for 10 min 
7. Air dried for approximately 1 hour to evaporate ethanol 
8. Resuspend in dH2O. 
Reagent Stock 
Concentration 
Required 
concentration/amount 
Volume 
Forward Primer 20 µM 10 pmol 0.5 µl 
Reverse Primer 20 µM 10 pmol 0.5 µl 
dNTPs (Bioline, UK) 5 mM 200 µM 1 µl 
Colorless GoTaq reaction 
buffer (Promega, USA) 
5x 1x 5 µl 
GoTaq DNA polymerase 
(Promega, USA) 
10 U/µl 1 U 0.1 µl 
Sterile distilled H2O   16.9 µl 
Template DNA 100 ng/µl 100 ng 1 µl 
Total Volume   25 µl 
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Appendix I: Correlations between side effects 
Table A: Correlations between twenty side effects investigated in this study. Abbreviations:  Corr: Correlation (r2 value); Sig.: p-value; N: number of patients; 
Nau: Nausea; Dia: Diarrhoea; Trem: Tremor; Polyd: Polydipsia; Polyu: Polyuria; Mem: Memory and Concentration problems; Bod: Bodyache; Drow: 
Drowsiness; Cons: Constipation; Indi: Indigestion; Dry: Dry Mouth; Head: Headache; Stuf: Stuffy Nose; Wei: Weight gain; Met: Metallic Taste; App: Poor 
appetite; Diz: Dizziness/Giddiness; Blur: Blurred vision; Thy: Thyroid problems; Skin: Skin problems   
 Nau Dia Trem Polyd Polyu Mem Bod Drow Cons Indi Dry Head Stuf Wei Met App Diz Blur Thy Skin 
Nau 
Corr 1 .220
*
 .281
**
 .257
*
 .228
*
 .000 .225
*
 .236
*
 .082 .323
**
 .145 .154 -.019 .066 .166 -.060 .159 .218
*
 .121 .141 
Sig.  .028 .005 .010 .027 .998 .024 .017 .413 .001 .151 .125 .853 .513 .099 .549 .111 .029 .229 .161 
N 101 100 100 99 94 100 101 101 101 101 99 101 101 100 100 101 101 101 100 101 
Diar 
Corr .220
*
 1 .146 .140 .195 .067 .250
*
 .090 .063 -.014 .198
*
 -.002 -.028 .043 .016 .071 .033 .196
*
 .042 -.038 
Sig. .028  .144 .164 .057 .502 .011 .366 .526 .888 .047 .986 .779 .669 .871 .478 .741 .047 .672 .700 
N 100 103 102 100 96 102 103 103 103 103 101 103 103 102 102 103 103 103 102 103 
Trem 
Corr .281
**
 .146 1 .206
*
 .102 .015 .135 .026 .076 .233
*
 .221
*
 .209
*
 .132 .125 .226
*
 -.082 .101 .173 -.107 -.068 
Sig. .005 .144  .038 .321 .881 .171 .790 .444 .017 .026 .033 .182 .207 .022 .406 .309 .080 .281 .494 
N 100 102 104 101 96 103 104 104 104 104 102 104 104 103 103 104 104 104 103 104 
Polydip 
Corr .257
*
 .140 .206
*
 1 .563
**
 -.068 .191 .086 .203
*
 .070 .535
**
 .143 .157 .150 .086 .051 .157 .163 .055 .028 
Sig. .010 .164 .038  .000 .498 .054 .389 .040 .482 .000 .153 .114 .134 .393 .609 .115 .101 .584 .777 
N 99 100 101 102 96 101 102 102 102 102 101 102 102 101 101 102 102 102 101 102 
Polyu 
Corr .228
*
 .195 .102 .563
**
 1 -.067 .100 .361
**
 .137 .057 .381
**
 .036 .178 .212
*
 .058 .243
*
 .111 -.030 .070 .007 
Sig. .027 .057 .321 .000  .516 .332 .000 .180 .581 .000 .727 .081 .038 .572 .016 .280 .767 .498 .946 
N 94 96 96 96 97 96 97 97 97 97 96 97 97 96 96 97 97 97 96 97 
Mem 
Corr .000 .067 .015 -.068 -.067 1 .130 .162 .111 -.031 .199
*
 -.075 -.066 .066 .122 .231
*
 .245
*
 .217
*
 -.042 -.142 
Sig. .998 .502 .881 .498 .516  .189 .099 .261 .758 .045 .448 .506 .508 .220 .018 .012 .027 .674 .149 
N 100 102 103 101 96 104 104 104 104 104 102 104 104 103 103 104 104 104 103 104 
Bod 
Corr .225
*
 .250
*
 .135 .191 .100 .130 1 .046 .040 .193
*
 .153 .185 .360
**
 .162 .166 -.031 .356
**
 .363
**
 .012 .080 
Sig. .024 .011 .171 .054 .332 .189  .644 .686 .048 .123 .058 .000 .100 .093 .752 .000 .000 .903 .415 
N 101 103 104 102 97 104 105 105 105 105 103 105 105 104 104 105 105 105 104 105 
Drow 
Corr .236
*
 .090 .026 .086 .361
**
 .162 .046 1 -.059 .115 .183 .030 -.020 .273
**
 -.075 .060 .033 .237
*
 .165 .014 
Sig. .017 .366 .790 .389 .000 .099 .644  .549 .244 .065 .762 .841 .005 .447 .542 .736 .015 .094 .888 
N 101 103 104 102 97 104 105 105 105 105 103 105 105 104 104 105 105 105 104 105 
Cons 
Corr .082 .063 .076 .203
*
 .137 .111 .040 -.059 1 .349
**
 .115 .029 .136 -.097 .020 -.077 .135 -.060 .148 -.054 
Sig. .413 .526 .444 .040 .180 .261 .686 .549  .000 .246 .770 .168 .327 .842 .435 .169 .546 .133 .585 
N 101 103 104 102 97 104 105 105 105 105 103 105 105 104 104 105 105 105 104 105 
Indi 
Corr .323
**
 -.014 .233
*
 .070 .057 -.031 .193
*
 .115 .349
**
 1 .033 .290
**
 .105 .027 .182 -.016 .224
*
 .121 .035 .130 
Sig. .001 .888 .017 .482 .581 .758 .048 .244 .000  .738 .003 .286 .783 .064 .871 .022 .217 .721 .185 
N 101 103 104 102 97 104 105 105 105 105 103 105 105 104 104 105 105 105 104 105 
141 
 
 Nau Dia Trem Polyd Polyu Mem Bod Drow Cons Indi Dry Head Stuf Wei Met App Diz Blur Thy Skin 
  
Dry 
Corr .145 .198
*
 .221
*
 .535
**
 .381
**
 .199
*
 .153 .183 .115 .033 1 .185 .105 .246
*
 .230
*
 .007 .201
*
 .097 .199
*
 .059 
Sig. .151 .047 .026 .000 .000 .045 .123 .065 .246 .738  .061 .292 .013 .020 .943 .042 .328 .045 .554 
N 99 101 102 101 96 102 103 103 103 103 103 103 103 102 102 103 103 103 102 103 
Head 
Corr .154 -.002 .209
*
 .143 .036 -.075 .185 .030 .029 .290
**
 .185 1 .313
**
 .269
**
 .222
*
 .116 .004 .242
*
 -.028 .320
**
 
Sig. .125 .986 .033 .153 .727 .448 .058 .762 .770 .003 .061  .001 .006 .023 .239 .969 .013 .779 .001 
N 101 103 104 102 97 104 105 105 105 105 103 105 105 104 104 105 105 105 104 105 
Stuf 
Corr -.019 -.028 .132 .157 .178 -.066 .360
**
 -.020 .136 .105 .105 .313
**
 1 .044 .153 .111 .145 -.007 -.068 .115 
Sig. .853 .779 .182 .114 .081 .506 .000 .841 .168 .286 .292 .001  .660 .120 .259 .139 .946 .495 .243 
N 101 103 104 102 97 104 105 105 105 105 103 105 105 104 104 105 105 105 104 105 
Wei 
Corr .066 .043 .125 .150 .212
*
 .066 .162 .273
**
 -.097 .027 .246
*
 .269
**
 .044 1 .215
*
 .203
*
 .120 .179 .112 .071 
Sig. .513 .669 .207 .134 .038 .508 .100 .005 .327 .783 .013 .006 .660  .029 .039 .224 .068 .259 .473 
N 100 102 103 101 96 103 104 104 104 104 102 104 104 104 103 104 104 104 104 104 
Met 
Corr .166 .016 .226
*
 .086 .058 .122 .166 -.075 .020 .182 .230
*
 .222
*
 .153 .215
*
 1 .225
*
 .344
**
 .224
*
 .012 .176 
Sig. .099 .871 .022 .393 .572 .220 .093 .447 .842 .064 .020 .023 .120 .029  .022 .000 .022 .902 .074 
N 100 102 103 101 96 103 104 104 104 104 102 104 104 103 104 104 104 104 103 104 
App 
Corr -.060 .071 -.082 .051 .243
*
 .231
*
 -.031 .060 -.077 -.016 .007 .116 .111 .203
*
 .225
*
 1 .005 .005 -.031 -.028 
Sig. .549 .478 .406 .609 .016 .018 .752 .542 .435 .871 .943 .239 .259 .039 .022  .960 .959 .753 .779 
N 101 103 104 102 97 104 105 105 105 105 103 105 105 104 104 105 105 105 104 105 
Diz 
Corr .159 .033 .101 .157 .111 .245
*
 .356
**
 .033 .135 .224
*
 .201
*
 .004 .145 .120 .344
**
 .005 1 .260
**
 .142 .168 
Sig. .111 .741 .309 .115 .280 .012 .000 .736 .169 .022 .042 .969 .139 .224 .000 .960  .007 .151 .087 
N 101 103 104 102 97 104 105 105 105 105 103 105 105 104 104 105 105 105 104 105 
Blur 
Corr .218
*
 .196
*
 .173 .163 -.030 .217
*
 .363
**
 .237
*
 -.060 .121 .097 .242
*
 -.007 .179 .224
*
 .005 .260
**
 1 .108 .245
*
 
Sig. .029 .047 .080 .101 .767 .027 .000 .015 .546 .217 .328 .013 .946 .068 .022 .959 .007  .274 .012 
N 101 103 104 102 97 104 105 105 105 105 103 105 105 104 104 105 105 105 104 105 
Thy 
Corr .121 .042 -.107 .055 .070 -.042 .012 .165 .148 .035 .199
*
 -.028 -.068 .112 .012 -.031 .142 .108 1 .344
**
 
Sig. .229 .672 .281 .584 .498 .674 .903 .094 .133 .721 .045 .779 .495 .259 .902 .753 .151 .274  .000 
N 100 102 103 101 96 103 104 104 104 104 102 104 104 104 103 104 104 104 104 104 
Skin 
Corr .141 -.038 -.068 .028 .007 -.142 .080 .014 -.054 .130 .059 .320
**
 .115 .071 .176 -.028 .168 .245
*
 .344
**
 1 
Sig. .161 .700 .494 .777 .946 .149 .415 .888 .585 .185 .554 .001 .243 .473 .074 .779 .087 .012 .000  
N 101 103 104 102 97 104 105 105 105 105 103 105 105 104 104 105 105 105 104 105 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
